

A Scoping Review of Current and Emerging Techniques for Evaluation of Peripheral Nerve Health, Degeneration and Regeneration: Part 2, Non-Invasive Imaging

Ross Mandeville, MD¹, Swati Deshmukh, MD², Ek Tsoon Tan, PhD³, Viksit Kumar, PhD⁴, Benjamin Sanchez, PhD⁵, Arriyan Dowlatshahi, MD⁶, Justin Luk⁷, Reiner See, MD⁸, Carl Leochico, MD⁹, Jas Thum, MD⁷, Stanley Bazarek, MD, PhD¹⁰, Benjamin Johnston, MD, PhD¹⁰, Justin Brown, MD⁷, Jim Wu, MD², Darryl Sneag, MD³, Seward Rutkove, MD¹

¹ Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02215 USA

² Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA 02215 USA

³ Department of Radiology, Hospital for Special Surgery, New York, NY 10021 USA

⁴ Department of Radiology, Massachusetts General Hospital, Boston MA 02114 USA

⁵ Department Electrical and Computer Engineering, University of Utah, Salt Lake City, UT 84112 USA

⁶ Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA 02215 USA

⁷ Department of Neurosurgery, Massachusetts General Hospital, Boston MA 02114 USA

⁸ Department of Neurology, Massachusetts General Hospital, Boston MA 02114 USA

⁹ Department of Physical Medicine and Rehabilitation, St. Luke's Medical Center, Global City, Taguig, Philippines

¹⁰ Department of Neurosurgery, Brigham and Women's Hospital, Boston MA 02115 USA

E-mail: rmandevi@bidmc.harvard.edu

Abstract

Peripheral neuroregenerative research and therapeutic options are expanding exponentially. With this expansion comes an increasing need to reliably evaluate and quantify nerve health. Valid and responsive measures of the nerve status are essential for both clinical and research purposes for diagnosis, longitudinal follow-up, and monitoring the impact of any intervention. Furthermore, novel biomarkers can elucidate regenerative mechanisms and open new avenues for research. Without such measures, clinical decision-making is impaired, and research becomes more costly, time-consuming, and sometimes infeasible. Part 1 of this two-part scoping review focused on neurophysiology. In Part 2, we identify and critically examine many current and emerging non-invasive imaging techniques that have the potential to evaluate peripheral nerve health, particularly from the perspective of regenerative therapies and research.

Keywords: Nerve regeneration, Peripheral nerve imaging, Muscle imaging, Quantitative, MR Neurography, Neuromuscular Ultrasound

Introduction

Peripheral nerves are vital to how we perceive and interact with our environment and each other; even mild injury can lead to life-changing consequences¹⁻³. Without the protection of bone, and often being very superficial and vulnerable, peripheral nerves are frequently damaged in diverse ways, both traumatically and spontaneously^{4,5}. The combination of their importance and the prevalence of injury makes the management of peripheral nerve pathology one of the greatest challenges to our society. Fortunately, rapid expansion is occurring in therapies designed to promote peripheral reinnervation or slow degeneration across a multitude of conditions⁶⁻¹⁰. However, without accurate quantification and characterization of nerve health, clinical decision-making, translation of neurorestorative therapies, and indeed generation of new therapeutic lines of research are slowed by an order of magnitude. Generally, peripheral nerve evaluation continues to rely heavily on clinical examination and standard neurophysiology, especially in the clinical domain. These standard investigations attempt to classify by spatial distribution, presence of demyelination or axon loss, and severity to inform the pathological process and guide management. In animal research, invasive histological markers, basic neurophysiology, and behavior tend to be most employed. The capacity to quantify axonal integrity or detect degenerating and regenerating nerve fibers, essential for evaluating nerve health and regeneration, is rarely evaluated from a non-invasive imaging perspective.

This scoping review represents Part 2 of a two-part review on current and emerging techniques in the evaluation of nerve health. In Part 1, we performed a scoping review of the same subject but focused on neurophysiological techniques¹¹ (in submission). In Part 2, the objective is firstly to cast a wide net to systematically identify and collate non-invasive imaging techniques that can, or have a reasonable potential to, evaluate peripheral nerve health, including approaches and techniques that may have not previously been applied to peripheral nerve. Our second objective is to provide commentary on their value, practicality, and future direction from a cross-specialty perspective. The goal is to provide a broad foundation from where effective clinical and research design decisions can be tailored, as well as to highlight and encourage areas of basic and translational science that may prove fruitful in advancing peripheral nerve imaging. The scope of the review is limited to non-invasive or intraoperative techniques. This is in part due to the burgeoning literature and advances in more invasive imaging techniques and microscopy that bridge across the fields of histology and imaging. The boundaries are not clear-cut, and subjective decisions have been made as to which techniques fall within the scope of this review, with magnetic resonance, ultrasound, and photoacoustic based imaging techniques representing its backbone.

Nerve health can be quantified in many ways that can be categorized grossly into structure and function. While many excellent reviews exist that are concerned with assessing varied polyneuropathies and entrapment neuropathies using extraneural gross morphology, including demyelinating conditions, this review predominantly focuses on imaging the state of innervation and histological structure pertinent to degeneration and regeneration, regardless of the pathological mechanisms of injury. Beyond quantifying the axonal quality and number, even a nerve devoid of axons has a level of health associated with it that is vital to understand clinically and in research; the nerve may be so degenerated as to not accept new axons, or it may be primed by Wallerian degeneration to spur axonal regeneration, and differentiating such characteristics is essential for optimizing outcomes.

1
2
3 While a formal systematic review is not possible when hypothesis generation is the goal, a scoping
4 review methodology¹² was applied to ensure wide coverage of potential techniques, including
5 techniques that may have yet to be applied to peripheral nerve. We briefly review the more common
6 current approaches to imaging peripheral nerves before focusing on selected promising and emerging
7 techniques that were identified with the aid of the structured scoping searches in combination with
8 discussion among authors selected for their variety of specialties and experience.
9

10
11 The companion scoping review of the same subject but focused on neurophysiology (under review)
12 assesses nerve functionality, complementing the more structurally oriented measures discussed within
13 this review. However, imaging and neurophysiology are not the only methods of assessing nerve; it
14 should be emphasized when deciding on research design or clinical management, the entire range of
15 nerve evaluation approaches need to be considered including, histological and lab-based assays, clinical
16 exam, patient reported outcomes, survival, and behavior¹³. Next, we discussed methodology of the
17 review and the results prior to discussing the imaging techniques from the perspective of validity,
18 practicality, and future direction.
19
20

21 Methods

22
23 The same methodology was applied as that of the companion review focused on neurophysiology
24 (under review). The scoping review involved a search of PubMed, Embase, Web of Science, and Google
25 Scholar¹² to answer the question “what imaging techniques currently assess peripheral nerve health in
26 clinical and research practice, and what are the techniques that show promise?”. Using PRISMA-ScR^{14,15}
27 guidelines and aid from our institutions librarians, we developed a comprehensive search strategy to
28 identify published and gray literature sources. Briefly, the initial limited search using title, abstract and
29 associated index terms in PubMed, along with iterative discussion among authors and colleagues,
30 curated the list of terms for inclusion of current and potential techniques. The second search applied
31 these terms across all 4 databases, which included a Google Scholar search through screening of the first
32 400 records. Search results were augmented by review of the references of selected articles, as well as
33 review of thoughts on future directions that may indicate additional potential or emerging techniques.
34 We did not apply restrictions on language, dates, or article type. Imaging search terms (such as MR
35 neurography, ultrasound, photoacoustic) were connected via “AND” Boolean statements to nerve
36 health statements (such as injury, regeneration, denervation, neuropathy). “NOT” statements (referring
37 to unrelated disorders and anatomy) were used to refine result numbers, and these were collected
38 during the initial limited PubMed search.
39
40
41
42

43 Any technology that had the potential to image nerve non-invasively or intraoperatively was initially
44 deemed eligible for further consideration. This included imaging techniques that allowed monitoring
45 over time and at a depth of at least several millimeters. Given the absence of a clearly demarcated line
46 dividing invasive and non-invasive imaging techniques, as well as time and resource constraints, those
47 techniques on the border of inclusion were identified and separately discussed as to appropriateness of
48 inclusion or not amongst the study authors. Of note, most microscopy techniques were considered out
49 of scope due to being generally limited to sub-millimeter depths and usually requiring more invasive
50 methods. Some methods overlapped with the scoping review focused on neurophysiology; most
51 notably, electrical impedance tomography (EIT), which is an imaging modality but included in the
52 neurophysiology review due to its provenance and significant component of neurophysiology.
53 Additionally, imaging technologies that could be used to stimulate a nerve action potential were
54
55
56
57
58
59
60

included in the review focused on neurophysiology including, ultrasound, magnetic resonance, and optical stimulation. We included evaluation of muscle as a surrogate for nerve health because it is so closely related with motor axons and nerve health. Sources referring to standard imaging were excluded but discussed while referencing established textbooks and seminal articles; however, if the source described a novel implementation of standard techniques, this was included. After iterative discussion amongst the authors, articles were selected based on their contribution in terms of performance characteristics, practicality, and underlying mechanisms and suggestions for future advances. Final searches were completed in March 2023 and processed using Covidence and Zotero software. Although, a degree of subjectivity was unavoidable, bias was minimized by using broad and a priori search protocols, as well as the involvement of cross-disciplinary authors.

Results

The results of the scoping search are detailed below in the flow diagram (Fig 1). The search of the 4 databases returned 2711 texts. Titles and abstracts of all texts were reviewed by the authors, as well as the references of those selected as most informative about performance characteristics and mechanisms. This resulted in 533 texts deemed relevant for the relationship between imaging and nerve health, and full texts were downloaded. Authors discussed and critically evaluated the articles, selecting those most relevant to performance characteristics, mechanisms, and potential as a measure of nerve health to be included for discussion and referencing in the review (265 texts).




Figure 1: Search Flow Chart. MRI: Magnetic Resonance Imaging.

1. MAGNETIC RESONANCE IMAGING TECHNIQUES

1.1 Neuromuscular MRI

MRI has long evaluated gross extraneural peripheral nerve structural abnormalities such as nerve continuity and intra- or extraneural masses¹⁶. However, advances in spatial resolution and processing, as well as more availability of clinical MRI with higher magnetic field strengths (3 or 7 Tesla), now make

1
2
3 MRI increasingly suitable for evaluating internal fascicular architecture¹⁷⁻²². Secondary signal alterations
4 in denervated muscle offers further insight into nerve health in a conceptually similar manner to
5 studying muscle neurophysiology with electromyography (EMG)^{23,24}, and interest in muscle
6 quantification is growing as the realization of its diagnostic utility is becoming clearer.

7
8 MR technology continues to advance rapidly in the assessment of both nerve and muscle. An array of
9 current and emerging quantitative MR approaches to neuromuscular evaluation are briefly reviewed
10 below.

11 12 1.1.1 MR Neurography

13 The term 'MR neurography' (MRN), coined in the early 1990s, refers to the application of specific MR
14 pulse sequences to improve peripheral nerve visualization²⁵⁻²⁷. Generally, fascicular bundles are
15 isointense to slightly hyperintense to muscle on T2-weighted pulse sequences²¹. Fat suppression is
16 important to increase contrast between nerves and adjacent soft tissues, mainly muscle. Vascular
17 suppression techniques may also be useful to suppress slow-flowing vessels that can confound reliable
18 identification of adjacent peripheral nerves¹⁷. Administering intravenous gadolinium contrast is useful to
19 evaluate nerve tumors and inflammation, but generally is not needed in the setting of traumatic nerve
20 injury¹⁷, aside from its use for vascular suppression with 3D MRI techniques²⁸.

21
22 Using 3 Tesla clinical MRI scanners and phased-array surface coils, modern day strategies maximize
23 nerve-to-background contrast and spatial resolution by applying fast spin-echo (FSE) T2-weighted
24 sequences (echo time (TE) of ~80ms), with additional fat and flow suppression²⁹, including use of Dixon
25 FSE³⁰ that takes advantage of the phase differential between spins at water and fat resonances. Since
26 the introduction of these approaches, detailed anatomical images of nerve with enhanced
27 characterization of pathology has been possible clinically and in the lab^{27,31,32}. Discussed below are some
28 new and emerging quantification methods, many that have been well validated in central nervous
29 system imaging, and although residing in the realm of research at this time with none being standard
30 care, many have the potential to mature into viable biomarkers and progress MRN's capability in
31 assessing peripheral nerve health.

32 1.1.2 Three-Dimensional Analysis

33 3D-volume neurography and photograph-like images from cinematic rendering augment standard
34 MRN³³. The ability to rotate and view from any angle is not only diagnostically useful for radiologists, but
35 also helpful in communicating results to referring clinicians³⁴. Sequences such as 3D fast (turbo) spin-
36 echo (FSE or TSE; vendor-specific acronyms include VISTA, SPACE, and CUBE) provide high-spatial and
37 high-contrast resolution that enable detection and visualization of subtle alterations in nerve contour,
38 signal intensity, and 3D nerve fascicular reconstruction³⁵. The combination of diffusion-weighted (DW)
39 sequences with 3D approaches has been championed the last few years, for instance in the form of DW
40 reversed fast imaging with steady-state precession (3D DW-PSIF) sequences^{21,35}, although it has not yet
41 been adopted widely in clinical practice or research, potentially due to added time and cost. Volumetric
42 MRI of the dorsal root ganglia has been studied to determine if it is a valid non-invasive in-vivo measure
43 of neuron loss after distal axotomy³⁶, finding good correlation to histology ($r=0.67$). Overall, 3D imaging
44 does not replace 2D imaging due to less sharpness and lower in-plane (about 1mm compared to 0.4-
45 0.5mm in 2D imaging, a significant difference)³⁷.

1.1.3 Diffusion Imaging

The application of diffusion weighted imaging (DWI) and most critically diffusion-tensor imaging (DTI) created much excitement in recent years because of its ability to interrogate nerve anisotropy. Anisotropy refers to the directional dependence of a physical measure. In the case of nerves, the tube-like character of fascicles, which preferentially restricts the naturally occurring Brownian motion of water molecules in the longitudinal plane, produces anisotropy that is detectable with these techniques. In addition to allowing selective nerve




Fig 2. Diffusion tractography overlays of the mid-forearm median nerve with a peripheral nerve sheath tumor on sagittal (A) and axial (B) proton density MR images. Adapted with permission from John Wiley and Sons, Sneag *et al.*, *JMRI*, 2020.

visualization, several derived parameters are readily quantifiable, including the apparent diffusion coefficient (ADC) and for DTI, fractional anisotropy (FA)^{38–40}, which allows inferences about orientation and tissue architectural organization^{39,41,42}. Diffusion schemes in at least six “gradient” directions for DTI allows for the generation of 3D visualization (diffusion tensor tractography (DTT), Fig 2) of nerve fiber tracts^{32,43,44}. DTT is one of the few diagnostic techniques that has been specifically assessed within the field of nerve regeneration through comparison with histological and functional parameters of recovery. It has been found capable of depicting tract termination at the injury site, as well as distal fiber growth, and also correlates with neurophysiological and functional recovery in humans^{39,45–52}. Furthermore, mean FA has been shown to correlate well with the number of large axons within healthy, uninjured nerves⁴⁷, suggesting a potential role in donor nerve selection for nerve transfer surgery, although this finding requires corroboration and validation in injured nerve. Regeneration reestablishes both fascicular structure and myelination, and therefore anisotropy, resulting in progressively increasing FA and axial diffusivity (AD), and decreasing radial diffusivity (RD) values, while ADC and mean diffusivity (MD) values normalize as edema resolves^{39,53}. DTI does not, however, appear to correlate with severity of axonal injury⁴⁷ and results obtained in the controlled environment of lab-based research, with the ability to study *ex vivo* or only straight nerve segments, have not translated to the more challenging case of *in vivo* clinical research or practice. Jeon *et al.*⁵⁴ reviewed some of the unique obstacles posed by peripheral nerve imaging that have impeded clinical uptake, including the challenges of spatial and contrast resolution, non-linear nature of nerves, off-isocenter imaging, before offering practical approaches to mitigate against these concerns. Improvements to signal-to-noise (SNR) using principal component analysis with generalized spherical deconvolution⁵⁵ may partially address the high variance in diffusion parameters within healthy and injured nerve, and across scanners⁵⁴. Due to single-shot echo-planar sequences being so susceptible to even small inhomogeneities in the magnetic field with poorer fat suppression, Martín-Noguerol *et al.* found that non-single-shot echo-planar DTI aids significantly, especially in the more challenging clinical contexts associated with trauma and artifact^{56,57}. Given the importance of vascularity in nerve injury and regeneration, recent approaches have sought to combine vascular (intravoxel incoherent motion (IVIM)) and DTI to depict both anisotropic microcirculation and microstructure simultaneously in rat sciatic nerve with some success^{58,59}. Part of the importance of DTI is that it elucidates the microarchitecture of nerves from a very different vantage point and dimension to the more standard structural resolution of anatomic imaging techniques

1
2
3 because of its reliance on molecular movement associated with complex diffusion patterns within the
4 nerve. Ultra-high field strength has been combined with DTI successfully, achieving a structural
5 resolution of (0.2 x 0.2mm) while overcoming the DTI distortion artifacts associated with increasing field
6 strengths⁶⁰. Although significant hurdles exist and advancements in coil design, post processing, and
7 pulse sequences are required⁵⁴, these parameters are some of the most intuitively appealing and may
8 yield potentially useful biomarkers capable of robustly evaluating nerve degeneration and regeneration
9 at depth in the near future including, axonal number and integrity^{39,61}.

12 1.1.4 Magnetic Susceptibility Imaging

13 Magnetic susceptibility⁶² is an alternative key contrast mechanism that has predominantly been used to
14 image the cerebral venous system and comes in two forms. Susceptibility-weighted imaging (SWI), signal
15 dephasing near tissue interfaces, transformed bothersome susceptibility artefact into a method of
16 enhancing contrast between tissues. Subsequently, the development of quantitative susceptibility
17 mapping (QSM) allowed detailed charting of magnetic source characteristics⁶³, and has been used to
18 evaluate myelin in the brain. The ability of QSM to quantify differences in iron deposition, myelin, and
19 oxygen saturation suggests this may be a feasible marker of peripheral nerve health in certain
20 circumstances. Detection of iron in macrophages or myelin may inform on Wallerian degeneration or
21 detect an increase in myelin that might correspond with increasing axons and regeneration. However,
22 this remains a nascent technique in peripheral nerve evaluation and requires additional refinement to
23 address the small size of nerves and complicated phase behavior from interference from sources of
24 susceptibility external to the nerves such as air-tissue interfaces, subcutaneous fat and bone, and
25 intraneural lipid-equivalent tissues⁶³.

30 1.1.5 Magnetic Transfer

31 Magnetization transfer^{64,65} (MT) generates tissue contrast based on magnetization exchange between
32 free and restricted protons, represented by collagen, myelin, and axonal proteins. This makes it
33 particularly interesting for measuring denervation and reinnervation and it has been shown to be a
34 sensitive metric of myelin density changes caused by both demyelination and axonal loss⁶⁶⁻⁶⁸. Beyond
35 simply axonal content and state of myelin, a sensitivity to collagen is of interest in chronic denervation
36 states. Delays in nerve repair are frequent and the window of opportunity to reinnervate nerve and
37 muscle is little more than a year⁶⁹; the ability to detect collagenization⁷⁰ may help personalize
38 treatment, preventing futile surgeries and missed opportunities. Nevertheless, the need for high spatial
39 resolution and SNR when imaging peripheral nerve presents a particular challenge for quantitative
40 measurements in nerve using MT imaging³⁷.

41 A multiparametric approach^{56,63}, overlaying and weighting the above MR nerve imaging approaches
42 (such as DTI, SWI, MT) based on clinical context, as well as potentially post-processing of neural
43 morphometrics⁶³, may provide a richer assessment of nerve health than any marker alone. Quantitative
44 MRN parameters were assessed in SMA (spinal muscular atrophy)^{71,72}, including T2 relaxation time
45 (increased), proton spin density (decreased), cross sectional area (decreased), with differences found to
46 be clearly statistically significant, as well as correlation with neurophysiology. SMA is a different model
47 of nerve health compared to the more common demyelinating, entrapment neuropathy, or nerve injury
48 models. It represents only loss of motor axons, as also occurs in ALS (amyotrophic lateral sclerosis).
49 Given that perhaps the majority of a nerve, even a motor nerve^{73,74}, is made up of non-motor axons, the
50 significant differences found in SMA suggest even greater differences should be found in other models
51
52
53
54
55
56
57
58
59
60

1
2
3 that include sensory axon loss because pathological changes and tissue contrast will not be diluted or
4 obscured by the presence of a great amount of unaffected sensory neural tissue and axons.
5

6 1.1.6 Nerve Selective Contrast Agents

7 The blood-nerve barrier (BNB) and subsequent lack of selectivity for nerve has hindered the utility of
8 contrast in nerve evaluation. Conversely, the BNB could be used to identify areas of injury or where the
9 BNB may be regenerating or degenerating; BNB breakdown encompasses the entire distal trunk in
10 Wallerian degeneration, for instance, and repair appears to closely follow nerve outgrowth from the
11 proximal stump⁷⁵. To take advantage of this, contrast agents have been developed that accumulate
12 selectively in nerve⁷⁶. Gadofluorine M (GFM) accumulates in fibers undergoing Wallerian degeneration,
13 fades with remyelination in parallel with regrowth of nerve fibers, and persists in non-regenerating
14 nerve, which has clear implications for evaluating nerve regeneration. However, such contrast agents
15 have not been approved by the US Food and Drug Administration (FDA).
16
17
18

19 Superparamagnetic iron oxide (SPIO) particles, including ultrasmall SPIO particles, are applied for cellular
20 and molecular imaging because of their biocompatibility and ability to generate localized hypointense T2
21 and T2* areas^{77,78}. SPIO particles are rapidly phagocytized by macrophages, whose accumulation in
22 nerve undergoing Wallerian degeneration can then be followed from day 1 to 8⁷⁷ before fading.
23 Additional agents have been developed and some FDA approved including polyaminocarboxylate
24 chelates, which induce hyperintense signal on T1-weighted MR images³⁵. Some exciting advances
25 include nanoparticles (nanoneurotracers) functionalized with an antibody for targeted deployment in
26 combination with high field strength MRI^{79–81}; these could be developed for selective imaging of multiple
27 cell types⁸¹. Label-free imaging will always be preferable, but the selectivity and strength of signal
28 achievable with safe and target-specific labels and contrast agents likely represents the field that will
29 most advance resolution and quantification of nerve health, in particular in the lab, but with a trade-off
30 clinically due to the delay associated with FDA approval.
31
32
33

34 1.2.1 Quantitative Muscle MR

35 As with Ultrasound (US) and EMG, evaluation of muscle acts as a surrogate marker of nerve injury due to
36 denervation-related changes and is a highly useful complement to any assessment of nerve injury and
37 regeneration^{82–85}. On MRI, acute and subacute denervation demonstrates normal T1 but diffuse high
38 intensity on T2 fluid-sensitive sequences because of increased extracellular fluid space (“edema
39 pattern”), whose timing seems to parallel Wallerian denervation starting around 4 days, or even as soon
40 as 24 hours in rats^{24,86}. However, in chronic denervation, muscle precursor stem cells differentiate into
41 adipose cells and fibroblasts⁸⁷, which results in increased T1 fatty signal, as well as atrophy. These
42 characteristics, as well as changes in anisotropy secondary to reduced muscle fiber diameter⁸⁸, can be
43 exploited to provide multiparametric quantitative measures (qMRI). Fat Fraction (FF), T2 mapping,
44 apparent fiber diameter (AFD), and DTI/MT ratio of the muscle are all capable of providing *indirect* in
45 vivo measures of axonal loss^{67,82,83}. Nevertheless, further validation of each of the muscle MR
46 parameters, as well as the multi-parametric approach, is required to characterize the longitudinal
47 relationship between these muscle metrics and the state of the innervating nerve, as well as the
48 muscle’s receptivity to being re-innervated. Collateral reinnervation is expected to warp the relationship
49 between muscle signal and innervation status; up to 80% of axons may potentially be lost before
50 collateral reinnervation fails and muscle fibers remain denervated^{89,90}.
51
52
53
54
55
56
57
58
59
60

Volumetric assessment of muscle has been recently found to be a responsive outcome measure of reinnervation when standardized to BMI (body mass index)⁹¹; it represents another quantitative surrogate marker of nerve health and could be used in conjunction with additional MR imaging biomarkers. Similar to chronic denervation of nerve, chronic denervation of muscle after a year or so appears to also result in such degeneration, atrophy, fibrosis, and fatty replacement that the muscle can no longer be reinnervated; however, there is some debate over whether it is the distal nerve or muscle itself that is primarily unreceptive to new axons⁶. Regardless, quantitative muscle biomarkers sensitive to change in the chronic period (between one and two years being the most clinically important^{6,69}) would further address the clinical question of whether a repair would be futile or successful.

1.2.2 MR Elastography

MR elastography (MRE) offers similar benefits to US-based elastography methods discussed below but remains to be explored in the evaluation of peripheral nerve. Three requisite steps involve producing mechanical waves, adopting a modified phase-contrast MR sequence to image the wave, and applying an inversion algorithm to create an elastogram⁹². MRE has been applied in many organs, including the liver, brain, and muscle, but not in peripheral nerve likely due to limited spatial resolution that results from the reduced number of waves and volume averaging effects on the waves detected. In muscle⁹³, Basford et al. found stiffness to correlate with neuromuscular pathology as well as active contraction; however, this study only included one patient with peripheral nerve involvement (polio) and showed significant differences to muscles paralyzed by central lesions. The relationship of elastography with physical stiffness in nerve and muscle offers an interesting correlate to the tactile assessment of nerve intraoperatively that often guides surgeons subjectively in their assessment of nerve health.

1.3 Motor Unit MRI (MUMRI)

An approach using diffusion-weighted magnetic resonance imaging (MRI) has recently been combined with in-scanner electrical stimulation to image individual MUs^{94,95}, Fig 3. Its potential for detecting muscle reinnervation is exciting, allowing simultaneous surveillance of multiple muscles for the presence




Fig 3. 3D motor unit MRI (MUMRI) of single motor units in the lower limbs of healthy volunteers. Liminal electrical stimulation was applied to the common peroneal nerve at the fibular head, and the 3D structure of up to six motor units was reconstructed from multi-slice DWI images sensitive to motor unit contraction. 3D MUMRI reveals a more complex human motor unit structure than previously thought, with several units splitting and re-forming along their length. *Heskamp et al., 2022, available via CC BY 4.0.*

of actively or passively stimulated MUs. This capability may allow for the detection of nascent MUs, or the detection of sparse residual MUs allowing for rapid and non-invasive confirmation of nerve in continuity over a wide field of view, both important for surgical decision making as well as quantifying motor nerve health and changes over time non-invasively. The relative size and shape of MUs might also be used as a surrogate for denervation in a conceptually similar way that EMG MU size correlates with denervation, although the fascicular or volumetric constraints of MU area may reduce validity of this approach.

Modality	Stage	Resolution/Metric	Advantages	Disadvantages	Select References
MRN	C	0.3-0.4mm (in-plane)	Provides high spatial resolution	Subjective	25–27,29–32
3D MRN	C	0.6-1mm (in-plane)	If obtained isotropically, can be easily reformatted into arbitrary planes	Less sharp compared to 2D imaging	21,33–37
DTI	E	0.15mm (in-plane)	Quantifies microstructural change, identifies tracts and fiber growth, FA may correlate with axon number	Lower spatial resolution compared to qualitative imaging; susceptible to distortion and field inhomogeneity	32,38–61
QSM	E	Signal intensity	Sensitive to myelin and iron (macrophages)	Poor resolution, interference	62,63
MT	E	Signal intensity	Sensitive to collagen, myelin, and axon proteins	Poor resolution	37,64–68,70
MR Contrast agents	E	Signal intensity	Detect WD	Not FDA approved, safety	35,76–81
MR Muscle quantification	E	Multiparametric continuous variables	Larger target tissue, less resolution needed, may correlate with receptivity of muscle to reinnervation	Surrogate for nerve, changes may reflect collateral reinnervation and disuse	24,67,82,83,86,88
MR Muscle volume	E	Volume in mm ³	Easily quantifiable	Surrogate for nerve, changes may reflect collateral reinnervation and disuse	91
MR Elastography	P	Single continuous variable in muscle; kPA or velocity.	May correlate with receptivity of muscle to reinnervation, may correlate with level of innervation	Surrogate for nerve, changes may reflect collateral reinnervation and disuse. Unclear if measurement of nerve is feasible due to resolution.	92,93
MUMRI	P	Unknown volume (mm ³) of MU detectable	Detection of nascent or residual MUs, quantifies over time, MU size	MU size anatomically constrained, activating non-standard or deeper muscles may be difficult	94,95

C: currently in clinic use for nerve; I: currently used intraoperatively for nerve; L: currently in lab use for nerve; E: emerging for nerve; P: potential but untested in nerve. MRN: MR neurography, 3D: 3 dimensional, 2D: 2 dimensional, DTI: diffusion tensor imaging, QSM: quantitative susceptibility mapping, MT: Magnetization Transfer, MUMRI: motor unit MRI, FA: fractional anisotropy, WD: Wallerian degeneration, MU: motor unit

2. ULTRASOUND BASED IMAGING TECHNIQUES

2.1 Neuromuscular Ultrasonography (NMUS)

As with MRI, technical advances in ultrasound hardware and signal processing are rapidly finding applications in neuromuscular medicine, research, and training⁹⁶⁻¹⁰⁰. Neuromuscular physicians and researchers have realized the significant benefits of ultrasound in evaluating nerves and muscles, including its widespread availability, low cost, high resolution, dynamic capability to explore large areas of nerves, and painlessness^{97,101}. As a result, over the last few decades, ultrasound has been increasingly used standalone as well as contemporaneous with neurophysiology⁹⁸. NMUS is presently used to obtain basic qualitative and quantitative measures of nerve and muscle such as echogenicity, the presence of nearby structural changes, and cross-sectional area. For the most part, pathological nerve cross-sectional area increases and its echogenicity decreases, while muscle, which can again be used as a surrogate for nerve health, atrophies and becomes more echogenic⁹⁸. Unfortunately, beyond myelination abnormalities^{102,103}, routine ultrasound provides little information regarding the innervation state of a nerve, including Wallerian degeneration, regeneration, or axonal content. Fascicles within a nerve, appearing as a honeycomb in cross-section on ultrasound, can be easily identified, and in the early days of nerve ultrasonography researchers had hoped to exploit this characteristic and detect a relationship to axonal content. However, the observed fascicles represent a fraction of the true number, a difference exacerbated as probe frequency decreases^{104,105}. Standard neuronal ultrasonographic characteristics vary little with Wallerian degeneration¹⁰⁴, chronic denervation^{106,107}, or reinnervation, perhaps because the most salient aspect of B-mode nerve imaging relies on scattering properties of the connective tissue enveloping the axons and not the axons themselves¹⁰⁴. Unless degenerated or lost axons are replaced by material that scatters ultrasound signals in a distinctively different manner, or gross cross-sectional area changes commensurably, basic quantitative techniques will struggle to meaningfully quantify the level of denervation. As discussed below, new developments in objective quantitation are on the horizon that may be able to not only serve as biomarkers but also provide insights into pathophysiology.

2.2 Quantitative Muscle Ultrasound

Muscle ultrasound clinically is usually performed qualitatively, which again suffers from dependence on examiner experience and a lack of reliability. Quantification aims to first enhance reliability in detecting




Fig 4. Left: normal muscle echogenicity. Right: severely denervated muscle echogenicity with increased subcutaneous tissue and obliteration of bone echo.

what is usually subjectively obvious, with the hope that this is followed by enhanced sensitivity and specificity. While the Heckmatt scale is occasionally used when semi-objectively quantifying muscle ultrasound images¹⁰⁸, it suffers from a subjective component, is not a continuous scale, and reliability has been questioned¹⁰⁹. Nevertheless, muscle is substantially easier to examine than nerve using standard

quantitative ultrasound techniques (Fig 4), such as those that rely on calibrated grayscale or backscatter imaging. Grayscale echo intensity is usually analyzed offline via simple computer-assisted grayscale histogram analysis. Originally, there was concern that compression of backscatter data into 256 grayscale levels by proprietary software resulted in unwanted bias; however, significant differences have not been found between methods employing backscatter and grayscale levels, resulting in most studies relying on the more accessible grayscale metric. These techniques estimate the acoustic energy reflected to the transducer^{110–115}, and calibration is always required for optimal standardization. Unfortunately, reference values are not only highly device-dependent, but they require much effort to obtain¹⁰⁹. Simple and rapid standardization techniques have been attempted¹¹⁶, but the variability of parameters involved in image generation between ultrasound machines restricts the application to longitudinal within subject studies using the same machine¹¹⁶, and preferably the same examiner. Nevertheless, once proprietary algorithmic manipulation is removed, it appears reliability may be significantly improved¹¹⁷. This represents a promising avenue for improvement in quantitative muscle ultrasound. As discussed below, other methods have yielded positive results beyond standard mean grayscale analysis.

2.2.1 Ultrasound of denervated muscle

Although fewer studies have assessed the performance of quantitative ultrasound in denervated muscle (predominantly ALS) compared to primary muscle pathologies, relationships have been found between the level of pathology and echointensity^{111–114,118}. Unlike MRI, ultrasound is unfortunately not able to detect early edema seen in denervation¹¹⁹. In general, studies attempt to predict the presence, absence, and category of muscle disease¹²⁰, and far fewer have explicitly focused on the level of muscle denervation, which would be the most relevant marker for nerve health. In this regard, initial findings with more advanced methods have managed to detect differences in muscle type and gender, using higher-order texture abstractions that rely upon spatial variations of pixel intensities to reflect muscle microstructure, being less susceptible to device characteristics.^{121,122}

2.2.2 Heterogenous muscle signal in ultrasound

Heterogeneity of muscle echo intensity has not been explored significantly. This may be important for nerve injury and regeneration, which can have patchy involvement of axons innervating any given muscle due to neural architecture inhibiting nerve growth outside of a MU's territory or across fascicular boundaries⁶ in severely denervated muscle (moth-eaten pattern). Visually depicting the echo intensity throughout the muscle as a topographical map, with hills of different heights and areas, it becomes possible to quantify areas affected rather than simply the mean echointensity across the entire muscle that is less sensitive to changes in muscle fiber innervation. As discussed earlier, the potential for a muscle to lose most of its innervation before collateral reinnervation fails^{89,90} renders ultrasound less sensitive to peripheral nerve injury or degeneration compared to primary muscle disease, but it may be able to inform in the early stages of reinnervation or late stages of denervation.

2.2.3 Dynamic ultrasound imaging

Already established in the detection of fasciculations^{115,123,124}, and quantifiable using speckle tracking of tissue motion¹²⁵, dynamic ultrasound imaging has the unique potential to comment on the presence of nascent units (small motor units currently undergoing reinnervation)¹²⁶ and fibrillations^{127–129}, albeit with the small size of both being a complicating factor^{130,131}. Such an approach might augment or even replace components of the EMG study when reviewing for muscle reinnervation; compared to needle EMG, its ability to rapidly review multiple muscles in their entirety and avoid the limitation of EMG's

1
2
3 small sampling area and invasiveness strongly favor the use of dynamic ultrasound if feasible^{115,123}.
4 Similar to the superiority of US over EMG in detecting fasciculations¹³², the combination of US with EMG
5 significantly increased the chances of detecting residual MUs after nerve trauma¹³³, a finding vital to
6 preventing unnecessary surgery and likely improving outcomes. This was followed by further enhanced
7 sensitivity in MU detection using nerve stimulation in addition to US guided EMG¹³⁴. No comparative
8 studies have been performed between EMG and ultrasound in detecting nascent units; despite the
9 smaller size of nascent MUs, the combination of US and EMG, potentially also with stimulation, will
10 likely outperform standard EMG alone. The presence or absence of motor units is not the only
11 information that speckle tracking of tissue motion may provide. Akin to the concept of MUMRI
12 discussed above, if quantifiable, the *anatomical* size of individual motor units might be informative in a
13 conceptually similar manner to the information contained within the size of its electrical MUP
14 counterpart measured with EMG; although, if collateral reinnervation does not cross fascicular
15 boundaries¹³⁵, this relationship will be distorted.

19 2.2.4 Ultrasound Muscle Elastography

20 B-mode imaging provides information on acoustic impedance, structure, and motion of a muscle;
21 however, beyond the field of neuromuscular evaluation, the technique of ultrasound elastography is
22 widely used to assess in real-time the mechanical properties of tissues, including stiffness¹³⁶. Denervated
23 muscle histology changes over time, with healthy muscle replaced by connective tissue and fat,
24 progressively becoming more difficult to reverse over a year or two^{6,137}. It has been hypothesized these
25 histological changes translate into differences in stiffness detectable by elastography¹⁰⁹. Some of the
26 main elastography techniques and related studies in denervated muscle are briefly discussed below.

27 Strain elastography¹³⁸⁻¹⁴¹ (SE) uses speckle pattern tracking to quantify tissue deformation after applying
28 pressure. The lack of pressure information (elastic modulus) and subjective grading are significant
29 disadvantages compared to other techniques. Few studies in denervated muscle or nerve have been
30 performed, with some promise seen when evaluating muscle in ALS, although no significant correlation
31 to nerve health was found in carpal tunnel syndrome¹⁴⁰.

32 Acoustic radiation force impulse (ARFI) imaging is based on similar principles to strain elastography¹⁴²;
33 however, it overcomes the lack of a standardized pressure pulse by implementing a fixed focused
34 ultrasound “push” beam, which consists of a prolonged burst of pulses¹⁴³. Nevertheless, because the
35 stress produced by ARFI is unknown, output images are again qualitative maps of tissue. Furthermore,
36 data acquisition can be limited due to overheating caused by the substantial power requirement to
37 produce the push beam¹⁴³. A form of ARFI, the Viscoelastic Response¹⁴⁴, can be used to measure muscle
38 fiber direction through muscle anisotropy. To our knowledge, neither of these techniques appears to
39 have been studied in denervated muscle.

40 Shear Wave Elastography (SWE) overcomes the limitations associated with both the applied stress and
41 objective measurement (Fig 5). A push beam like ARFI is used to generate a shear wave inside the tissue.
42 The propagating shear wave is tracked using pulse-echo techniques and shear wave velocity is estimated
43 by solving the shear wave equations using advanced mathematic modeling¹⁴⁵, calculation of
44 stiffness^{146,147} (tissue modulus), and generation of quantitative shear wave velocity maps. There are
45 drawbacks, including muscle anisotropy requiring the transducer to be oriented longitudinally along the
46 muscle, otherwise accuracy and reliability suffer¹⁴⁸. This becomes particularly problematic when we
47 consider the variability of muscle pennation, which makes it challenging to ensure correct orientation.

On the flip side, such anisotropy might represent a useful biomarker if it correlates with levels of denervation, or chronicity of denervation, and would be an interesting avenue to explore further.

While predominantly studied in primary muscle disease¹⁴³, several studies have also evaluated SWE of muscle in focal nerve entrapment and motor neuron disease^{120,149,150}, with mixed results due to high variance in healthy tissue, a lack of reference values, and variability between machines¹⁵⁰. Stiffness




Fig 5: Muscle Ultrasound. Left: trapezius under contraction. Right: Same muscle relaxed. kPa: kilopascal.

echogenicity matrix (SEM)¹⁵¹ is a recent novel approach looking to leverage complementary characteristics of two modalities; SWE and B-mode echo intensity. Research into the use of both SWE and B-mode imaging in evaluating muscle remains in its infancy, but a multiparametric approach may represent a more viable path forward in the evaluation of nerve health using muscle SWE given the described limitations of each modality individually.

2.3 Quantitative Nerve Ultrasound

Compared to muscle, there is significantly less research into applying advanced ultrasound techniques to nerve, but it is coming. As mentioned, this paucity of research stems from the small caliber of nerves, the architecture of their connective tissue, and the limits of resolution of commercial scanners. However, several groups are actively advancing quantitative ultrasound neurography¹⁵².

Akin to quantitative muscle ultrasound, backscatter and grayscale approaches have successfully distinguished between normal and pathological nerves at a group level, particularly in entrapment syndromes and diabetic polyneuropathy (DPN), and especially when examining ratios between fascicular and non-fascicular tissue termed "nerve density"^{153–155}. Although intraneural quantitative methods have not been found superior to simple gross nerve cross-sectional area measurements in detecting the presence of entrapment neuropathies¹⁵⁶, Tagliafico did show a relationship between median nerve hypointensity and severity of carpal tunnel syndrome (CTS), which may relate to increased edema rather than change in axonal content¹⁵⁷. Most studies to date are focused on detecting the presence or absence of a pathology (entrapment neuropathy or polyneuropathy, usually), and few quantify the severity of pathology or level of innervation. Beyond standard grayscale quantitation, the future of quantitative nerve ultrasound may lie more in several technologies discussed below.

Of note, techniques based on ultrasound stimulation¹⁵⁸ are discussed in the companion review of the same subject focused on neurophysiology because of the associated neuromodulation and the generation of action potentials; although, discussion of this interesting field could equally reside in this

review. Additionally, while beyond the scope of this review, it is worth mentioning that ultrasound's versatility and accessibility mean that it is commonly used as an adjunct in the evaluation of nerve health - for instance, to locate nerve for needle electrode placement during neurophysiologic assessment of nerve (stimulation and recording).

2.3.1 Ultra-High Frequency Ultrasound (UHF-US) of Nerve

Beyond improved fascicular identification¹⁰⁵, ultra-high-resolution ultrasound of nerves (Fig 6) has rarely been studied. Frequencies are generally described as being between 30 and 100 MHz¹⁵⁹, although no agreed threshold exists, and resolution as high as 20 μ m¹⁵⁹⁻¹⁶¹, as compared to standard clinic based ultrasounds with 10MHz probes at around 150 μ m, 100 μ m with 17MHz probes, and 73 μ m with 22MHz probes, at shallow depths^{162,163}. However, recently, Brya¹⁶⁴ examined the correlation of intra-fascicular 30-MHz ultrasound backscatter-based coefficients to collagen and myelin content in cadaver ulnar nerve fascicles. Moderately good correlation was found between backscatter and collagen (0.56), less so with myelin (0.2), but highest when combined (0.68). Similar findings using the gray-level co-occurrence matrix suggest this approach may also be applied without access to RF data¹⁶⁴. Given the limited penetration depth of UHF-US, its importance may ultimately lie intraoperatively, either stand-alone or potentially as a component of multi-modal photoacoustic techniques discussed below^{165,166}. Although studies remain pending, should they be able to provide information such as that related to axonal content, changes along a nerve suggestive of regeneration, or outline intact fascicles within neuromas, there would be immediate clinical and research utility.




Fig 6: 70 MHz Ultra-high frequency ultrasound image of median nerve at the wrist showing individual fascicles.

2.3.2 Ultrasound Nerve Elastography

The last few years have seen significant interest in the potential of elastography to comment on nerve pathology, especially for the mechanical changes associated with entrapment neuropathies and polyneuropathy^{152,167}. The sensitivity and specificity of SWE (Fig 7) and strain elastography are higher than CSA for diabetic polyneuropathy, with high reproducibility¹⁶⁸⁻¹⁷². However, it is unclear whether the severity of neuropathy correlates highly with SWE values, which histological changes result in elastography changes, and whether these findings are likely to translate to other pathologies such as denervation and regeneration. Furthermore, complexity in using SWE has been highlighted by several studies¹⁷³⁻¹⁷⁷ which demonstrated SWE measurements vary depending on where along the nerve the measurement is taken, whether in transverse or longitudinal axis, which nerve is measured, and gender, but not significantly by age, BMI, weight, or height. Furthermore, tensile force, limb position, depth, device platform, and ROI size also impact measurements¹⁷⁷⁻¹⁸³, and the effect of nerve diameter is likely significant once a threshold is met due to fewer shear wavelengths and volume effects^{152,176}. The numerous elastography studies in CTS have had varying results^{152,184}. Although a pilot study using strain elastography in CTS did not show significant correlation¹⁴⁰, several have looked at SWE in CTS, finding slightly less diagnostic ability than CSA and variable correlation with severity¹⁸⁵⁻¹⁹⁰. A modest

improvement of clinimetrics was seen when US metrics were combined, with application of intra-nerve comparison^{186,187,191,192}. Given the wide range of values in healthy individuals, the merit of SWE when




Fig 7: Cross-sectional SWE image of completely denervated median nerve at the wrist (A), and contralateral unaffected median nerve at the wrist (B), revealing pressure difference in KPa. Long axis measurements showed similar results, as did alterations in size of the region of interest. Median nerve area also differed, 6.3mm (A) versus 10.5mm (B). kPa: kilopascal.

evaluating nerve health may be in the longitudinal evaluation at the same location and in the same individual, or between groups of subjects. Using an intra-subject reference, more subtle changes that are associated with denervation or regeneration, such as histological alterations arising from new axonal growth, may be detectable and quantifiable. Recent animal sciatic crush studies demonstrated a remarkably tight correlation in SWE measurements longitudinally after sciatic crush^{193,194}, slowly increasing in stiffness over time, despite the arrival of axons in the later time periods (8 weeks). In this study, the ratio of the elastic modulus between measurements taken pre and post injury was used for intra-subject standardization, akin to ultrasound measurements for carpal tunnel syndrome assessing the CSA ratio between wrist and forearm¹⁹⁵. Additionally, there appeared to be little variation in ratio between the rodents within each group (standard deviation of 0.06) suggesting standardization to proximal nerve segment resulted in high reliability. These results appear generally more promising than studies in human nerve entrapment and polyneuropathy and the use of the crush injury model may be more valid in neuroregeneration research. However, characterizing SWE changes in different contexts will be important going forward, including until full reinnervation has completed and in chronic denervation states, as well as at different tissue depths.

2.3.3 Vascular and Contrast-enhanced Ultrasound

Standard color and power doppler ultrasound is unable to detect the slow flow within the microcirculation of nerve tissue¹⁹⁶. However, advances in Doppler (e.g., superb microvascular imaging) now permit the assessment of vascular changes in nerve^{188,191,197-200}. Intraneural hypervascularity may be caused by compression or inflammatory response, which is usually graded subjectively. When quantification via image-processing has been applied, intraneural vascularity correlated well with the severity of neuropathy^{188,201}. Intraneural vascular changes in Wallerian degeneration and the reinnervating growth cone have not been studied to our knowledge, and it is unclear if the perfusion and energy requirements within chronically denervated nerve are significantly different from a nerve with a full complement of axons, which may allow a further metric of nerve health. High-frequency contrast-enhanced US using microbubbles of inert gas has also successfully quantified peripheral nerve perfusion¹⁹⁶, which may turn out to be relevant in detecting vascular growth associated with regenerating nerve or even correlate with axon density. In a study into neurovascular coupling, the trigeminal ganglion was examined using microbubble tracking and a 15MHz ultrasound probe with an

ultrafast neuroimager, showing a significant hemodynamic response following afferent activation (corneal nociceptive)²⁰². This is interesting because the number of neurons that needed to be activated for a hemodynamic response to be detected was low (about 300 neurons) and suggests the neurovascular coupling of distal peripheral nerve might be able to be assessed similarly to sensory ganglia at such a detailed level.

Modality	Stage	Resolution/Metric	Advantages	Disadvantages	Select References
QUS Muscle	E	0.1-0.15mm	Easy to quantify, texture analysis promises higher sensitivity	Machine and operator dependent, collateral reinnervation obscures denervation level	109–118,120–122
Dynamic US	E	0.1-0.15mm, high frame rate allows fibrillation detection, Speckle tracking	Detection of residual or nascent units, possibly fibrillations	Non-target muscle movement obscuring target muscle movement	115,123–134
SWE Muscle	E	Kilopascal or velocity, greater than millimeter scale	Quantifies muscle stiffness important for receptivity to nerve	Reliability, many factors affect measurements, reference values lacking, collateral reinnervation obscures denervation level	109,120,136,143,148–151
UHF-US Nerve	E	0.073-0.1mm,	Higher resolution than MRI if superficial, distinguish fascicles, correlates with collagen and myelin, intraoperative use	Resolution reduces with depth more than a few centimeters	153–157,165,166
SWE Nerve	E	Kilopascal or velocity, greater than millimeter scale	Metric related to nerve mechanical properties, detects changes associated with WD	Reliability, many factors affect measurements, reference values lacking	152,167–179,181–194,203
CEUS	E	Assesses flow within intraneural microvessels	Improved resolution compared to doppler US	Need for contrast injection, untested in nerve injury	196
Doppler US, SMI	E	Assesses flow within intraneural microvessels	Vascular changes correlate with nerve health and WD	Surrogate marker, ordinal semi-objective quantification, low sensitivity, untested in nerve injury	188,191,197–199,201
PAI	E	4-400 μ m depending on ultrasound transducer	Structural, molecular, and functional information, high resolution	Portability, economic viability, restricted depth of imaging	204–221

C: currently in clinic use for nerve; I: currently used intraoperatively for nerve; L: currently in lab use for nerve; E: emerging for nerve; P: potential but untested in nerve. QUS: quantitative ultrasound, WD: Wallerian degeneration, CEUS: contrast enhanced US, SMI: superb microvascular imaging.

3. Photoacoustic Imaging (PAI)

Since uncovering the property of “sonorousness” inherent in different materials when exposed to rapidly-interrupted sunlight and the creation of a “*Photophone*” (Alexander Graham Bell²²²), it has been found that any wave in the electromagnetic spectrum is capable of inducing sound in tissue (acoustic

1 waves). Optical energy (electromagnetic waves) can be absorbed by molecules and subsequently
2 converted into heat, resulting in thermoelastic expansion. It is this movement that creates sound waves
3 that can be detected by ultrasound transducers. The combination of optical energy and acoustic
4 measurement has been described in several ways; perhaps the most graphic being Bell's "Photophone",
5 but more recently the most common terms are "photoacoustic" and "optoacoustic", although
6 "thermoacoustic" describes the general effect of sound induction through thermal expansion. Further
7 nomenclature that has arisen depends on the resolution obtained, field of view, frequencies and
8 exogenous contrast agents used, with additional common descriptors^{204,205} including tomography,
9 macroscopy, mesoscopy, microscopy, multispectral, label-free etc., the details of which are covered in
10 several excellent reviews^{204,206,223–229}.

11 The scalability of PAI has found an important role in bridging the sizeable gap between imaging
12 modalities that lie on the more invasive end of the spectrum, such as fluorescence microscopy, and
13 those less invasive techniques such as the previously discussed MRI and US modalities. PAI can
14 ultimately be thought of as an extension of US imaging albeit using a novel signal source and underlying
15 contrast mechanism; pulse-echo ultrasonography utilizes the mismatch in impedance between soft
16 tissues to image structures, whereas PAI utilizes the different characteristics of light-absorbing soft-
17 tissue chromophores. This means that PAI can capture not only structural features but importantly
18 extends to molecular and functional features²⁰⁷. Sound scatters far less than light in soft tissue, perhaps
19 1000 times less²³⁰, and as such the acoustic signal suffers significantly lower attenuation to allow much
20 greater depth of high resolution imaging; a near infrared window (NIR; 700–1700 nm) enables tissue
21 penetration depth up to several centimeters.²²⁵ The resulting resolution remains limited by the
22 attenuation of high-frequency ultrasonic waves in tissue, which results in a practical depth-to-resolution
23 ratio of up to 200²³¹; for example, at a depth of 5mm, resolution could be as high as 25 μ m^{208,209}.

24 PAI systems can be categorized via which optical illumination and acoustic detection methods are being
25 combined. PAI *Macroscopy*²⁰⁷ is capable of imaging up to several centimeters, relying on a non-focused
26 optical beam over a wider area and with detection in the range up to 10 MHz, with resolution up to
27 100 μ m. PAI *Mesoscopy*^{207,210,211} is similar in process but images up to several millimeters with resolution
28 achieved through increased ultrasonic frequency detection, up to 200 MHz with a resolution generally
29 found to be in the range of 50-100 μ m; although, some report up to 4 μ m axially 18 μ m transverse with
30 depths up to as much as 5 mm²⁰⁸. With the only difference between PAI macroscopy and PAI mesoscopy
31 being the transducer, this means that macroscopy and mesoscopy can readily be switched, allowing
32 easy scalability with little need to change equipment – a significant bonus for translatability to the
33 clinical environment. The third category is Photoacoustic *Microscopy*; it is considered beyond the scope
34 of this review due to the imaging depth being so low, but it is briefly described for the sake of
35 completeness. PAI microscopy is generally limited to sub-millimeter depths and utilizes an alternate
36 method of illumination that systematically moves a focused beam across the target (relying on optical
37 resolution, rather than acoustic resolution in macroscopy and mesoscopy), with each area detected
38 separately by the ultrasound transducer, which removes the need for tomographic techniques.
39 Resolution in this category of PAI can be down to the sub-micron level²¹².

40 Contrast in PAI has been shown to be a consequence of endogenous optical absorbers, including lipid,
41 lipofuscin, melanin, collagen, water, and hemoglobin^{213,214}. The inclusion of lipid in this list of
42 endogenous chromophores is of interest due to the myelin component of peripheral nerve^{217,220,221}. In
43 particular, the potential for measuring changes in the combination of endogenous chromophores such
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 as lipid²³², vascularity/hemoglobin²¹⁹, water, and collagenization within nerve offers exciting but as yet
4 mostly untapped future possibilities for evaluating nerve health and denervation in the acute and
5 chronic stages, importantly including Wallerian degeneration, chronic denervation, and regeneration.
6 Only a few studies have focused specifically on peripheral nerve evaluation and PAI^{215–221}. Matthews et
7 al. demonstrated peripheral nerve imaging proof-of-concept by imaging ex-vivo mouse sciatic nerve
8 embedded in chicken tissue. Although at submillimeter depths, resolution was measured as 41 μ m, and
9 the endogenous chromophore (contrast agent) was found to be the lipid content of the myelin. This is
10 encouraging for the measurement of regeneration and degeneration given the close relationship of
11 myelination to axon number, growth, and degeneration. Another study used multispectral laser
12 excitation, which adds to the resolution and specificity of PAI by localizing specific chromophores due to
13 differential light absorption characteristics²⁰⁶. Li et al.²²⁰ applied this multispectral PAI and demonstrated
14 a penetration depth up to 2.7cm; in this study, the group noted an axial resolution of 124 μ m when
15 performing in-vivo imaging in rodent at a depth of 2mm.
16
17
18

19 Endogenous chromophores are most preferable but are limited and often lack precision due to weak
20 optical absorption²²⁵, but exogenous chromophores are being developed at a rapid rate in attempts to
21 increase contrast of tissue^{223,225,229}. Although peripheral nerve represents a challenge due to the blood-
22 nerve barrier²³³, headway is being made²²³. As previously described, impermeability to contrast can be
23 used to highlight areas where the blood-nerve barrier has been disrupted, which is helpful in detecting
24 Wallerian degeneration and potentially neuronal growth cones; alternatively, it can potentially be
25 opened via various mechanisms to allow for contrast agent uptake²³⁴ and the imaging of intraneural
26 structural and molecular properties.
27
28

29 3.1 Obstacles and Future advances in PAI

30 PAI has numerous limitations and much scope for continued advancement in the field of peripheral
31 nerve imaging. The practicalities of creating a portable and economically viable system represents a
32 significant barrier but will be key for adoption rates. One approach to overcome this is focused on low
33 cost light emitting diodes (LED) to replace expensive lasers²³⁵. Traditional piezoelectric transducers have
34 put some constraints on PAI systems²³⁶ and studies have investigated improving the practicality of a PAI
35 system through the use of optical sensors; including transparent Fabry–Perot sensors in the place of
36 piezo transducers to allow simultaneous illumination of tissue and detection of ultrasound without the
37 transducer obscuring the laser²³⁷, as well as aid in miniaturization and reduction of interference²³⁸.
38 Optimal image processing is a necessity for effective imaging using PAI and represents its own
39 challenges. Here too, improvements are being made including algorithms to quantify images more
40 effectively through use of artificial intelligence and machine learning to extract as much information as
41 possible from the signal^{229,239–243}.
42
43
44
45

46 In attempts to improve resolution of PAI, several methods have been applied with some success²²⁴.
47 Localization-based approaches (localization optoacoustic tomography) uses rapid sequential acquisition
48 of 3D photoacoustic images to achieve sub-diffraction (below diffraction limits of the wavelength of light
49 used) spatial resolution and reduce artifact²⁴⁴. The inherent scattering nature of light within biological
50 tissues presents a substantial obstacle on the penetration depth of non-scattered photons²⁴⁵. Using
51 “wavefront shaping”^{245,246} to compensate for scattering, improvements of up to ten times in signal-to-
52 noise and six times sub-acoustic resolution have been achieved. Finally, the acoustic diffraction limit has
53 also been surpassed by using techniques that achieved super-resolution in microscopy²⁴⁷ (super-
54 resolution fluorescence fluctuation microscopy), which induced temporal fluctuations of fluorescence
55
56
57
58
59
60

using “blinking” fluorescence molecules. This approach was translated to PAI with good effect by exploiting multiple random speckle illuminations as the source of acoustic fluctuations²⁴⁸.

Advances in optical, ultrasonic, and image processing technology, along with the ability to image structural, molecular, and functional features, have resulted in PAI becoming one of the most exciting and fast improving modalities in non-invasive imaging at greater than millimeter depths. Improved targeting and resolution of contrast agents that are endogenous to nerve, or design of safe exogenous neural contrast agents, promises to provide unparalleled access to nerve health.

4. Multimodal Methods

4.1 Positron Emission Tomography (PET)

Damaged nerves uptake FDG-PET due to higher levels of metabolic demand from injury as well as increased firing rates²⁴⁹, yielding another promising imaging biomarker of nerve health. Interesting avenues of ongoing research include neuronal-selective contrast agents, rather than relying on metabolic demand, and the necessary combination with other modalities such as CT or MRI for enhanced spatial resolution^{250–252} that may have potential to inform on neuronal regeneration and degeneration. The combination of modalities not only increases neuronal structural resolution but also overlays another vital feature of nerve health, function, similar to photoacoustic techniques discussed above and highlights the benefit of dual modality approaches to imaging beyond just high-resolution structural detail.

4.2 Ultrasound Fusion

Medical image fusion involves overlaying images, or displaying side by side, from different imaging modalities after an initial co-registration and has gained widespread use in several medical specialties²⁵³. The combination of the two modalities (ultrasound images fused and co-located with pre-recorded MRI or CT images) not only allows practical guidance to obtain accurate recordings from otherwise hard to assess deep nerve and muscle, but also enables multimodal quantification of precisely located neuronal and muscular tissue, useful for assessing nerve health. Precisely stimulating and recording from deep nerve is challenging even with ultrasound guidance, but the combination with MRI overcomes this issue and augments the potential to assess nerve throughout the body. Fusion imaging represents the technological frontier of the ever closer relationship between neuromuscular ultrasound and neurophysiology, both in clinic and intra-operatively^{254–256}.

4.3 PAI Fusion

Pre-clinical studies have into multi-modal imaging of PAI with MRI²⁵⁷ and ultrasound^{216,228,258} have been demonstrated in recent years. Like PET fusion approaches, the goal is to exploit the complementary information provided by anatomical landmark imaging with the molecular and functional contrast offered by PAI. This has been used primarily in imaging gliomas to obtain clear borders, but the translatability to nerve is clear as shown by Ishihara in the evaluation of diabetic nerve²¹⁶; the combination of rapidly acquired gross structure with molecular content would be invaluable for assessing nerve health, making clinical decisions, and monitoring treatment effects on investigational regenerative therapies.

5. In-Vivo Lab and Intraoperative Imaging

5.1 MR Microneurography

Animal peripheral nerve imaging options expand beyond those available to humans and this offers distinct advantages and opportunities for improvement. For instance, high-resolution MR microneurography optimizes the spatial resolution of neurography images, using very high magnetic fields, extremely powerful gradients, and specific coils²⁵⁹. With a 9.4 Tesla scanner and gradients of 400mT/m, images of anatomical parts can be obtained with a spatial resolution of up to 30 μ m^{259–262}, far superior to clinical MRI resolution of approximately 0.4-0.5mm²⁶³, and several times greater than in-human microneurography methods, even with highly-restricted field of view, of a little over 100 μ m^{264,265}; although, SNR may be improved further in human studies using new acceleration methods^{266,267}. Such high resolution may detect intraneural structure at a level relevant to axonal content and nerve health evaluation, akin to a magnetic resonance nerve biopsy.

As mentioned, application of MR microneurography using 3 T scanners using a restricted field of view was capable of enough visualization of internal nerve structure to allow quantification nerve fascicle area, as well as perineurium and epineurium area, using a segmentation protocols^{264,268}. These areas were combined into a ratio (fascicle to nerve ratio), potentially relating to nerve pathology given significant correlation to demyelinating pathology²⁶⁸. Discussed below, this is a similar theme to fascicular ratios applied in ultrasound and are based on the rationale that different compartments within nerve differentially respond to pathological processes, providing reliable intraneural structural metrics beyond simply whole nerve cross-sectional area. The application to nerve evaluation would involve only a small segment of nerve being evaluated (“biopsied”) to understand in maximal possible detail the health of the nerve for clinical or surgical decision-making, or to accurately monitor degeneration, regeneration, and response to neurotherapeutics.

5.2 Ultra-High Frequency Ultrasound

The sonographic counterpart of MR Microneurography is the previously described UHF-US (section 2.3.1), also termed micro-ultrasound¹⁶⁵, and similar to US biomicroscopy^{269–271} (UBM) that has historically been applied in embryology research and subsequently ophthalmology, angiology, and dermatology. Limitations with mechanically scanned transducers have been overcome using phased array layouts²⁷¹ allowing the dedicated high-frequency probes from 30 to 100 MHz and more^{159,160} to increase the spatial resolution to the micron level (as low as 20 μ m), albeit at the expense of the investigation depth due to previously described inherent depth-to-resolution ratio of up to 200^{105,159,231}. The appropriateness of which ultrasound machine is used differs depending on environment, as exemplified by recent technological advances in clinical research machines allowing for ultra-high to low (70-1MHz) imaging capabilities (*Vevo F2 Fujifilm Visualsonics*). Such increased freedom of data access with open architecture, high performance multimodal imaging, and quantitative interfaces offers the opportunity for significantly more sophisticated techniques to be applied in controlled and laboratory environments.

5.3 Photoacoustic Alternative Forms of Microscopy

Photoacoustic techniques reviewed above are applicable to, and perhaps best suited to, in-vivo animal research. However, as mentioned, significant development of the systems and techniques are required. This review focuses predominantly on the more non-invasive peripheral nerve imaging techniques that are capable of depths of at least several millimeters. However, it is important to at least point to the

1
2
3 advances in numerous microscopy imaging techniques that are applicable at very shallow depths
4 (millimeter and below), which have exploded in recent years²³³ and include categories such as optical
5 microscopy^{272–275} and optical coherence tomography²⁷⁶ with and without fluorescence^{277–282} or
6 labelling²³³, as well as micro-CT^{283,284} and spectroscopy^{285,286}. Although considered beyond the scope of
7 this review, microscopy as a field has evolved far enough to require its own dedicated review focused on
8 invasive and ex-vivo imaging techniques for the evaluation of peripheral nerve health, degeneration,
9 and regeneration.
10
11

12 5.4. Intraoperative

13 The opportunity for direct access to nerve intraoperatively offers the opportunity for quite different
14 approaches to imaging, as well as greater resolution of modalities discussed already, such as
15 intraoperative ultrasound. Some techniques have already started to be applied clinically with several
16 emerging techniques at varying stages of development in the translational spectrum.
17
18

19 Neuromuscular ultrasound has found its place firmly in the outpatient clinic, not least the
20 neurophysiology lab due to the real-time addition of a structural correlate to concurrent
21 electrophysiological and clinical exam findings, and overlap in required anatomical knowledge^{287,288}. In
22 line with increasing interest in intraoperative peripheral nerve neurophysiology²⁸⁹, the natural extension
23 of this is into the intraoperative environment; direct access to nerve and muscle without intervening
24 tissue harnesses the full power of the highest frequencies. Recognition of its applicability
25 intraoperatively is rising steadily in the era of ultra-high frequencies^{290–292}, as well as its vascular and
26 sonoelastographic capabilities, and the argument for its place alongside intraoperative neurophysiology
27 is beginning to look similar to that of its clinic-based counterpart. The most obvious application is that of
28 ultra-high frequency ultrasound, with resolution up to 30µm using commercially available devices
29 (*VevoMD, Fujifilm Visualsonics*). Current benefits of its application intraoperatively are already manifold
30 including, nerve identification and mapping, and visualizing fascicular level detail to maximally spare
31 healthy tissue in delicate surgical approaches to peripheral nerve tumors and neuromas^{104,159,290,291,293–}
32 ²⁹⁷. If echotexture parameters can be discovered that indicate levels of denervation or collagenization,
33 then this would amplify its use immediately intraoperatively in evaluating nerve health, especially in
34 nerve injury surgery and exploration. Elastography of nerve, as discussed above, has shown promise in
35 evaluating nerve health and represents an intuitively appealing modality in peripheral nerve surgery.
36 Frequently, the firmness and texture of nerve, taken to be a surrogate for collagenization and fibrosis, is
37 subjectively determined by the surgeon in evaluating viability of nerve tissue; elastography speaks
38 directly to this firmness via evaluation of propagating wave velocity within the intraneural tissue.
39 However, as discussed above in section 2.3.2, there is a way to go before sensitive and specific
40 information can be extracted from ultrasonographic elastography signals of nerve. The degree, type, and
41 distribution of vascular changes are associated with nerve in different states of degeneration and
42 regeneration, and this could be an important biomarker of nerve health^{298,299}. One potential approach to
43 evaluating this potentially valid metric is intraoperatively with microvascular ultrasonography^{191,300,301}.
44 Such microvascular assessment could potentially also be attempted pre-operatively through use of
45 clinic-based ultrasound (discussed above), MR imaging²⁹⁸, or laser doppler techniques³⁰², but the access
46 provided intraoperatively allows enhanced resolution and offers a potential final check before
47 committing to the often nerve-racking and irreversible transection of a nerve.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In section 3, we discussed PAI and its application to the evaluation of nerve health. Intraoperative
4 use^{215,303} again takes advantage of the depth-to-resolution acoustic properties in PAI, greatly enhancing
5 likely resolution, similar to ultra-high frequency ultrasound but with reported potential resolution even
6 higher, approaching 4 μm ²⁰⁸. This level of resolution at sufficient depth with the added molecular and
7 potentially functional information provided by the differential tissue responses to thermoelastic stress
8 make PAI theoretically an ideal candidate for intraoperative use; as long as practicalities of integrating
9 acoustic and optical components be overcome in the challenging environment^{215,304,305} (discussed
10 above). Although discussed in the companion review focused on neurophysiology, it is worth also noting
11 here the intraoperative potential of electrical impedance tomography (EIT). This is an imaging modality
12 that benefits from direct access to nerve and provides the capability to image fascicular level
13 depolarization at resolutions below 200 μm ^{306,307}. In addition to the proposed role in neuromodulation,
14 especially of the vagus nerve, identifying fascicles that require repair in partial nerve injuries has long
15 been a problem in peripheral nerve surgery and would significantly help in recovery of function through
16 encouraging fascicular repair while also aiding in avoiding morbidity from unnecessary repairs.
17
18
19
20

21 7. Conclusion

22
23 The recent substantial increase in awareness from both clinical and research communities of the
24 promise of non-invasive nerve imaging is driving its rapid evolution across multiple modalities and
25 specialties. To unleash the exciting promise offered by so many imaging techniques identified and
26 discussed in this scoping review, advances in technology are needed to occur in tandem to achieve the
27 hoped-for exponential improvement in powerful and responsive imaging biomarker and outcome
28 measures to expedite progress in both neurotherapeutics and clinical practice. Many measures of nerve
29 health discussed in this review have seen high variance within healthy individuals, impacting their value
30 as a biomarker. Overcoming this will undoubtedly rely on technological advances but taking advantage
31 of combining modalities and techniques may represent low hanging fruit that can be rapidly exploited to
32 enhancement precision in the evaluation of nerve health.
33
34

35
36 The present scoping review serves as a complement to Part 1, which specifically concentrates on non-
37 neurophysiology¹¹. Some modalities straddle neurophysiology and imaging but have only been covered
38 by one of the reviews (such as EIT and ultrasound stimulation being covered within Part 1). Within the
39 combined reviews, we have covered an extensive assemblage of current and promising non-invasive
40 imaging and neurophysiological approaches, aiming to guide both the planning of peripheral
41 neuroregeneration research as well as the optimization of patient care. In addition to aiding in the
42 selection of appropriate metrics of nerve health, we have highlighted what we believe to be important
43 areas of promise and necessary avenues for further research.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bailey, R., Kaskutas, V., Fox, I., Baum, C. M. & Mackinnon, S. E. Effect of upper extremity nerve damage on activity participation, pain, depression, and quality of life. *J. Hand Surg.* **34**, 1682–1688 (2009).
2. Pain and Quality of Life Following Nerve Injury | 2010-10-01 | AHC.... *Relias Media | Online Continuing Medical Education | Relias Media - Continuing Medical Education Publishing* <https://www.reliasmedia.com/articles/20685-pain-and-quality-of-life-following-nerve-injury>.
3. Ciaramitaro, P. *et al.* Traumatic peripheral nerve injuries: epidemiological findings, neuropathic pain and quality of life in 158 patients. *J. Peripher. Nerv. Syst. JPNS* **15**, 120–127 (2010).
4. England, J. D. & Asbury, A. K. Peripheral neuropathy. *Lancet Lond. Engl.* **363**, 2151–2161 (2004).
5. Martyn, C. N. & Hughes, R. A. Epidemiology of peripheral neuropathy. *J. Neurol. Neurosurg. Psychiatry* **62**, 310–318 (1997).
6. Gordon, T. Peripheral Nerve Regeneration and Muscle Reinnervation. *Int. J. Mol. Sci.* **21**, 8652 (2020).
7. Bazarek, S. *et al.* Spinal motor neuron transplantation to enhance nerve reconstruction strategies: Towards a cell therapy. *Exp. Neurol.* 114054 (2022) doi:10.1016/j.expneurol.2022.114054.
8. Ghergherehchi, C. L. *et al.* Polyethylene glycol (PEG) and other bioactive solutions with neurorrhaphy for rapid and dramatic repair of peripheral nerve lesions by PEG-fusion. *J. Neurosci. Methods* **314**, 1–12 (2019).
9. Lanier, S. T., Hill, J. R., Dy, C. J. & Brogan, D. M. Evolving Techniques in Peripheral Nerve Regeneration. *J. Hand Surg.* **46**, 695–701 (2021).
10. Carvalho, C. R., Oliveira, J. M. & Reis, R. L. Modern Trends for Peripheral Nerve Repair and Regeneration: Beyond the Hollow Nerve Guidance Conduit. *Front. Bioeng. Biotechnol.* **7**, (2019).
11. Mandeville, R. *et al.* A Scoping Review of Current and Emerging Techniques for Evaluation of Peripheral Nerve Health, Degeneration, and Regeneration: Part 1, Neurophysiology. Manuscript Submitted for Publication. (2023).
12. Bramer, W. M., Rethlefsen, M. L., Kleijnen, J. & Franco, O. H. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. *Syst. Rev.* **6**, 245 (2017).
13. Wood, M. D., Kemp, S. W. P., Weber, C., Borschel, G. H. & Gordon, T. Outcome measures of peripheral nerve regeneration. *Ann. Anat. - Anat. Anz.* **193**, 321–333 (2011).
14. Tricco, A. C. *et al.* PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann. Intern. Med.* **169**, 467–473 (2018).
15. JBI Manual for Evidence Synthesis - JBI Global Wiki. <https://jbi-global-wiki.refined.site/space/MANUAL>.
16. Singh, T. & Kliot, M. Imaging of peripheral nerve tumors. *Neurosurg. Focus* **22**, 1–10 (2007).

17. Grant, G. A. *et al.* The utility of magnetic resonance imaging in evaluating peripheral nerve disorders. *Muscle Nerve* **25**, 314–331 (2002).
18. Bendszus, M. & Stoll, G. Technology Insight: visualizing peripheral nerve injury using MRI. *Nat. Clin. Pract. Neurol.* **1**, 45–53 (2005).
19. Stoll, G., Wilder-Smith, E. & Bendszus, M. Imaging of the peripheral nervous system. in *Handbook of Clinical Neurology* vol. 115 137–153 (Elsevier, 2013).
20. Kermarrec, E. *et al.* Ultrasound and Magnetic Resonance Imaging of the Peripheral Nerves: Current Techniques, Promising Directions, and Open Issues. *Semin. Musculoskelet. Radiol.* **14**, 463–472 (2010).
21. Chhabra, A. *et al.* MR Neurography: Past, Present, and Future. *Am. J. Roentgenol.* **197**, 583–591 (2011).
22. Deshmukh, S. & Samet, J. Ultrasonography of Peripheral Nerves. in *Atlas of Ultrasound-Guided Procedures in Interventional Pain Management* (ed. Narouze, S. N.) 289–296 (Springer, 2018). doi:10.1007/978-1-4939-7754-3_30.
23. Tan, E. T. *et al.* Quantitative MRI Differentiates Electromyography Severity Grades of Denervated Muscle in Neuropathy of the Brachial Plexus. *J. Magn. Reson. Imaging JMRI n/a*, 1104–1115 (2022).
24. Bendszus, M., Koltzenburg, M., Wessig, C. & Solymosi, L. Sequential MR Imaging of Denervated Muscle: Experimental Study. *Am. J. Neuroradiol.* **23**, 1427–1431 (2002).
25. Filler, A. G. *et al.* Magnetic resonance neurography. *Lancet Lond. Engl.* **341**, 659–661 (1993).
26. Magnetic Resonance Neurography - Howe - 1992 - Magnetic Resonance in Medicine - Wiley Online Library. <https://onlinelibrary.wiley.com/doi/abs/10.1002/mrm.1910280215>.
27. Cudlip, S. A., Howe, F. A., Griffiths, J. R. & Bell, B. A. Magnetic resonance neurography of peripheral nerve following experimental crush injury, and correlation with functional deficit. *J. Neurosurg.* **96**, 755–759 (2002).
28. Sneag, D. B. *et al.* Post-Contrast 3D Inversion Recovery Magnetic Resonance Neurography for Evaluation of Branch Nerves of the Brachial Plexus. *Eur. J. Radiol.* **132**, 109304 (2020).
29. Filler, A. G., Maravilla, K. R. & Tsuruda, J. S. MR neurography and muscle MR imaging for image diagnosis of disorders affecting the peripheral nerves and musculature. *Neurol. Clin.* **22**, 643–682 (2004).
30. Tan, E. T. *et al.* Improved nerve conspicuity with water-weighting and denoising in two-point Dixon magnetic resonance neurography. *Magn. Reson. Imaging* **79**, 103–111 (2021).
31. Vargas, M. I. *et al.* New approaches in imaging of the brachial plexus. *Eur. J. Radiol.* **74**, 403–410 (2010).
32. Sneag, D. B. & Queler, S. Technological Advancements in Magnetic Resonance Neurography. *Curr. Neurol. Neurosci. Rep.* **19**, 75 (2019).

33. Möller, I., Miguel, M., Bong, D. A., Zaottini, F. & Martinoli, C. The peripheral nerves: update on ultrasound and magnetic resonance imaging. *Clin. Exp. Rheumatol.* **36 Suppl 114**, 145–158 (2018).
34. Deshmukh, S., Tegtmeier, K., Kovour, M., Ahlawat, S. & Samet, J. Diagnostic contribution of contrast-enhanced 3D MR imaging of peripheral nerve pathology. *Skeletal Radiol.* **50**, 2509–2518 (2021).
35. Eppenberger, P., Andreisek, G. & Chhabra, A. Magnetic Resonance Neurography. *Neuroimaging Clin. N. Am.* **24**, 245–256 (2014).
36. West, C. A. *et al.* Volumetric magnetic resonance imaging of dorsal root ganglia for the objective quantitative assessment of neuron death after peripheral nerve injury. *Exp. Neurol.* **203**, 22–33 (2007).
37. Chhabra, A. *et al.* MR Neurography: Advances. *Radiol. Res. Pract.* **2013**, 1–14 (2013).
38. van der Jagt, P. K. N. *et al.* Architectural configuration and microstructural properties of the sacral plexus: A diffusion tensor MRI and fiber tractography study. *NeuroImage* **62**, 1792–1799 (2012).
39. Martín Nogueroles, T., Barousse, R., Socolovsky, M. & Luna, A. Quantitative magnetic resonance (MR) neurography for evaluation of peripheral nerves and plexus injuries. *Quant. Imaging Med. Surg.* **7**, 398–421 (2017).
40. Martín Nogueroles, T. & Barousse, R. Update in the evaluation of peripheral nerves by MRI, from morphological to functional neurography. *Radiologia* **62**, 90–101 (2020).
41. Simon, N. G., Lagopoulos, J., Gallagher, T., Kliot, M. & Kiernan, M. C. Peripheral nerve diffusion tensor imaging is reliable and reproducible: Reliability of Peripheral Nerve DTI. *J. Magn. Reson. Imaging* **43**, 962–969 (2016).
42. Cervantes, B. *et al.* Isotropic resolution diffusion tensor imaging of lumbosacral and sciatic nerves using a phase-corrected diffusion-prepared 3D turbo spin echo: Phase Corrected 3D TSE DTI of Lower Back Nerves. *Magn. Reson. Med.* **80**, 609–618 (2018).
43. Hiltunen, J. *et al.* Pre- and post-operative diffusion tensor imaging of the median nerve in carpal tunnel syndrome. *Eur. Radiol.* **22**, 1310–1319 (2012).
44. Skorpil, M., Karlsson, M. & Nordell, A. Peripheral nerve diffusion tensor imaging. *Magn. Reson. Imaging* **22**, 743–745 (2004).
45. Takagi, T. *et al.* Visualization of peripheral nerve degeneration and regeneration: Monitoring with diffusion tensor tractography. *NeuroImage* **44**, 884–892 (2009).
46. Lehmann, H. C., Zhang, J., Mori, S. & Sheikh, K. A. Diffusion tensor imaging to assess axonal regeneration in peripheral nerves. *Exp. Neurol.* **223**, 238–244 (2010).
47. Boyer, R. B. *et al.* 4.7-T diffusion tensor imaging of acute traumatic peripheral nerve injury. *Neurosurg. Focus* **39**, E9 (2015).
48. Simon, N. G. *et al.* Visualizing axon regeneration after peripheral nerve injury with magnetic resonance tractography. *Neurology* **83**, 1382–1384 (2014).

49. Meek, M. F., Stenekes, M. W., Hoogduin, H. M. & Nicolai, J.-P. A. In vivo three-dimensional reconstruction of human median nerves by diffusion tensor imaging. *Exp. Neurol.* **198**, 479–482 (2006).
50. Gallagher, T. A., Simon, N. G. & Kliot, M. Diffusion tensor imaging to visualize axons in the setting of nerve injury and recovery. *Neurosurg. Focus* **39**, E10 (2015).
51. Farinas, A. F. *et al.* Diffusion Magnetic Resonance Imaging Predicts Peripheral Nerve Recovery in a Rat Sciatic Nerve Injury Model: *Plast. Reconstr. Surg.* **145**, 949–956 (2020).
52. Farinas, A. F. *et al.* Diffusion tensor tractography to visualize axonal outgrowth and regeneration in a 4-cm reverse autograft sciatic nerve rabbit injury model. *Neurol. Res.* **41**, 257–264 (2019).
53. Andersson, G., Orådd, G., Sultan, F. & Novikov, L. N. In vivo Diffusion Tensor Imaging, Diffusion Kurtosis Imaging, and Tractography of a Sciatic Nerve Injury Model in Rat at 9.4T. *Sci. Rep.* **8**, 12911 (2018).
54. Jeon, T., Fung, M. M., Koch, K. M., Tan, E. T. & Sneag, D. B. Peripheral nerve diffusion tensor imaging: Overview, pitfalls, and future directions. *J. Magn. Reson. Imaging* **47**, 1171–1189 (2018).
55. Sneag, D. B. *et al.* Denoising of diffusion MRI improves peripheral nerve conspicuity and reproducibility. *J. Magn. Reson. Imaging* **51**, 1128–1137 (2020).
56. Martín Nogueroles, T. *et al.* Functional MR Neurography in Evaluation of Peripheral Nerve Trauma and Postsurgical Assessment. *Radiographics* **39**, 427–446 (2019).
57. Martín-Nogueroles, T., Montesinos, P., Barousse, R. & Luna, A. *RadioGraphics* Update: Functional MR Neurography in Evaluation of Peripheral Nerve Trauma and Postsurgical Assessment. *RadioGraphics* **41**, E40–E44 (2021).
58. Merchant, S., Yeoh, S., Mahan, M. A. & Hsu, E. W. Simultaneous Quantification of Anisotropic Microcirculation and Microstructure in Peripheral Nerve. *J. Clin. Med.* **11**, 3036 (2022).
59. Abdullah, O. M. *et al.* Orientation dependence of microcirculation-induced diffusion signal in anisotropic tissues: Organized Capillary Flow and Diffusion-Weighted Signal. *Magn. Reson. Med.* **76**, 1252–1262 (2016).
60. Schmid, A. B. *et al.* Feasibility of Diffusion Tensor and Morphologic Imaging of Peripheral Nerves at Ultra-High Field Strength. *Invest. Radiol.* **53**, 705–713 (2018).
61. Sheikh, K. A. Non-invasive imaging of nerve regeneration. *Exp. Neurol.* **223**, 72–76 (2010).
62. Haacke, E. M., Xu, Y., Cheng, Y.-C. N. & Reichenbach, J. R. Susceptibility weighted imaging (SWI). *Magn. Reson. Med.* **52**, 612–618 (2004).
63. Chen, Y., Haacke, E. M. & Li, J. Peripheral nerve magnetic resonance imaging. *F1000Research* **8**, F1000 Faculty Rev-1803 (2019).
64. Wolff, S. D. & Balaban, R. S. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. *Magn. Reson. Med.* **10**, 135–144 (1989).

65. Giorgetti, E. *et al.* Magnetic Resonance Imaging as a Biomarker in Rodent Peripheral Nerve Injury Models Reveals an Age-Related Impairment of Nerve Regeneration. *Sci. Rep.* **9**, 13508 (2019).
66. Dortch, R. D., Dethrage, L. M., Gore, J. C., Smith, S. A. & Li, J. Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases. *Neurology* **83**, 1545–1553 (2014).
67. Morrow, J. M. *et al.* MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. *Lancet Neurol.* **15**, 65–77 (2016).
68. Fan, S.-J. *et al.* Feasibility of quantitative ultrashort echo time (UTE)-based methods for MRI of peripheral nerve. *NMR Biomed.* **31**, e3948 (2018).
69. Brown, J. M., Shah, M. N. & Mackinnon, S. E. Distal nerve transfers: a biology-based rationale. *Neurosurg. Focus* **26**, E12 (2009).
70. Vuorinen, V., Siironen, J. & Røyttä, M. Axonal regeneration into chronically denervated distal stump. *Acta Neuropathol. (Berl.)* **89**, 209–218 (1995).
71. Kollmer, J. *et al.* Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy. *Neurology* **93**, e653–e664 (2019).
72. Kollmer, J. *et al.* Magnetization transfer ratio: a quantitative imaging biomarker for 5q spinal muscular atrophy. *Eur. J. Neurol.* **28**, 331–340 (2021).
73. Bromberg, M. B. The motor unit and quantitative electromyography. *Muscle Nerve* **61**, 131–142 (2020).
74. Gesslbauer, B. *et al.* Axonal components of nerves innervating the human arm: Arm Nerve Axonal Components. *Ann. Neurol.* **82**, 396–408 (2017).
75. Seitz, R. J. *et al.* The blood–nerve barrier in Wallerian degeneration: A sequential long-term study. *Muscle Nerve* **12**, 627–635 (1989).
76. Bendszus, M. *et al.* Assessment of nerve degeneration by gadofluorine M-enhanced magnetic resonance imaging: Nerve Regrowth Assessed by MRI. *Ann. Neurol.* **57**, 388–395 (2005).
77. Bendszus, M. & Stoll, G. Caught in the Act: *In Vivo* Mapping of Macrophage Infiltration in Nerve Injury by Magnetic Resonance Imaging. *J. Neurosci.* **23**, 10892–10896 (2003).
78. Chen, M.-W. *et al.* Monitoring of macrophage recruitment enhanced by Toll-like receptor 4 activation with MR imaging in nerve injury: MRI of Enhanced Macrophage Recruitment in Nerve Injury. *Muscle Nerve* **58**, 123–132 (2018).
79. Deddens, L. H., Van Tilborg, G. A. F., Mulder, W. J. M., De Vries, H. E. & Dijkhuizen, R. M. Imaging Neuroinflammation after Stroke: Current Status of Cellular and Molecular MRI Strategies. *Cerebrovasc. Dis.* **33**, 392–402 (2012).
80. Tereshenko, V. *et al.* MR Imaging of Peripheral Nerves Using Targeted Application of Contrast Agents: An Experimental Proof-of-Concept Study. *Front. Med.* **7**, 613138 (2020).

- 1
2
3 81. Janjic, J. M. & Gorantla, V. S. Peripheral Nerve Nanoimaging: Monitoring Treatment and
4 Regeneration. *AAPS J.* **19**, 1304–1316 (2017).
5
- 6 82. Tan, E. T., Zochowski, K. C. & Sneag, D. B. Diffusion MRI fiber diameter for muscle denervation
7 assessment. *Quant. Imaging Med. Surg.* **12**, 80–94 (2022).
8
- 9 83. Argentieri, E. C. *et al.* Quantitative T₂ -mapping magnetic resonance imaging for assessment of
10 muscle motor unit recruitment patterns. *Muscle Nerve* **63**, 703–709 (2021).
11
- 12 84. Lisle, D. & Johnstone, S. Usefulness of muscle denervation as an MRI sign of peripheral nerve
13 pathology. *Australas. Radiol.* **51**, 516–526 (2007).
14
- 15 85. Kamath, S., Venkatanarasimha, N., Walsh, M. A. & Hughes, P. M. MRI appearance of muscle
16 denervation. *Skeletal Radiol.* **37**, 397–404 (2008).
17
- 18 86. West, G. A. *et al.* Magnetic resonance imaging signal changes in denervated muscles after
19 peripheral nerve injury. *Neurosurgery* **35**, 1077–1085; discussion 1085-1086 (1994).
20
- 21 87. Agle, C. C., Rowleson, A. M., Velloso, C. P., Lazarus, N. R. & Harridge, S. D. R. Human skeletal
22 muscle fibroblasts, but not myogenic cells, readily undergo adipogenic differentiation. *J. Cell Sci.* **126**,
23 5610–5625 (2013).
24
- 25 88. Holl, N. *et al.* Diffusion-weighted MRI of denervated muscle: a clinical and experimental study.
26 *Skeletal Radiol.* **37**, 1111–1117 (2008).
27
- 28 89. Shefner, J. M. Motor unit number estimation in human neurological diseases and animal
29 models. *Clin. Neurophysiol.* **112**, 955–964 (2001).
30
- 31 90. Stalberg, E. V. Macro electromyography, an update. *Muscle Nerve* **44**, 292–302 (2011).
32
- 33 91. Wilcox, M. *et al.* Volumetric MRI is a promising outcome measure of muscle reinnervation. *Sci.*
34 *Rep.* **11**, 22433 (2021).
35
- 36 92. Low, G., Kruse, S. A. & Lomas, D. J. General review of magnetic resonance elastography. *World J.*
37 *Radiol.* **8**, 59–72 (2016).
38
- 39 93. Basford, J. R. *et al.* Evaluation of healthy and diseased muscle with magnetic resonance
40 elastography. *Arch. Phys. Med. Rehabil.* **83**, 1530–1536 (2002).
41
- 42 94. Birkbeck, M. G., Heskamp, L., Schofield, I. S., Blamire, A. M. & Whittaker, R. G. Non-invasive
43 imaging of single human motor units. *Clin. Neurophysiol.* **131**, 1399–1406 (2020).
44
- 45 95. Heskamp, L. *et al.* In vivo 3D imaging of human motor units in upper and lower limb muscles.
46 *Clin. Neurophysiol.* **141**, 91–100 (2022).
47
- 48 96. Cartwright, M. S. *et al.* A randomized trial of diagnostic ultrasound to improve outcomes in focal
49 neuropathies. *Muscle Nerve* **52**, 746–753 (2015).
50
- 51 97. Zaidman, C. M., Seelig, M. J., Baker, J. C., Mackinnon, S. E. & Pestronk, A. Detection of peripheral
52 nerve pathology. *Neurology* **80**, 1634–1640 (2013).
53
54
55
56
57
58
59
60

98. Walker, F. O., Cartwright, M. S., Wiesler, E. R. & Caress, J. Ultrasound of nerve and muscle. *Clin. Neurophysiol.* **115**, 495–507 (2004).
99. Tawfik, E. A. *et al.* Guidelines for neuromuscular ultrasound training. *Muscle Nerve* **60**, 361–366 (2019).
100. Carroll, A. & Simon, N. Current and future applications of ultrasound imaging in peripheral nerve disorders. *World J. Radiol.* **12**, 101–129 (2020).
101. Cartwright, M. S. & Walker, F. O. Neuromuscular ultrasound in common entrapment neuropathies. *Muscle Nerve* **48**, 696–704 (2013).
102. Zaidman, C. M. & Pestronk, A. Nerve size in chronic inflammatory demyelinating neuropathy varies with disease activity and therapy response over time: a retrospective ultrasound study. *Muscle Nerve* **50**, 733–738 (2014).
103. Beekman, R. *et al.* Ultrasonography shows extensive nerve enlargements in multifocal motor neuropathy. *Neurology* **65**, 305–307 (2005).
104. Silvestri, E. *et al.* Echotexture of peripheral nerves: correlation between US and histologic findings and criteria to differentiate tendons. *Radiology* **197**, 291–296 (1995).
105. Cartwright, M. S., Baute, V., Caress, J. B. & Walker, F. O. Ultrahigh-frequency ultrasound of fascicles in the median nerve at the wrist. *Muscle Nerve* **56**, 819–822 (2017).
106. Cartwright, M. S., Walker, F. O., Griffin, L. P. & Caress, J. B. Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis: Ultrasound in ALS. *Muscle Nerve* **44**, 346–351 (2011).
107. Hobson-Webb, L. D. Neuromuscular ultrasound in polyneuropathies and motor neuron disease. *Muscle Nerve* **47**, 790–804 (2013).
108. Heckmatt, J. Z., Leeman, S. & Dubowitz, V. Ultrasound imaging in the diagnosis of muscle disease. *J. Pediatr.* **101**, 656–660 (1982).
109. Wijntjes, J. & van Alfen, N. Muscle ultrasound: Present state and future opportunities. *Muscle Nerve* **63**, 455–466 (2021).
110. Pillen, S. *et al.* Quantitative skeletal muscle ultrasound: Diagnostic value in childhood neuromuscular disease. *Neuromuscul. Disord.* **17**, 509–516 (2007).
111. Zaidman, C. M., Connolly, A. M., Malkus, E. C., Florence, J. M. & Pestronk, A. Quantitative ultrasound using backscatter analysis in Duchenne and Becker muscular dystrophy. *Neuromuscul. Disord.* **20**, 805–809 (2010).
112. Jansen, M. *et al.* Quantitative muscle ultrasound is a promising longitudinal follow-up tool in Duchenne muscular dystrophy. *Neuromuscul. Disord.* **22**, 306–317 (2012).
113. Simon, N. G. *et al.* Quantitative ultrasound of denervated hand muscles. *Muscle Nerve* **52**, 221–230 (2015).

- 1
2
3 114. Zaidman, C. M., Holland, M. R., Anderson, C. C. & Pestronk, A. Calibrated quantitative ultrasound
4 imaging of skeletal muscle using backscatter analysis. *Muscle Nerve* **38**, 893–898 (2008).
5
6 115. Alfen, N. van & Mah, J. K. Neuromuscular Ultrasound: A New Tool in Your Toolbox. *Can. J.*
7 *Neurol. Sci.* **45**, 504–515 (2018).
8
9 116. Wu, J. S., Darras, B. T. & Rutkove, S. B. Assessing spinal muscular atrophy with quantitative
10 ultrasound. *Neurology* **75**, 526–531 (2010).
11
12 117. O’Brien, T. G., Cazares Gonzalez, M. L., Ghosh, P. S., Mandrekar, J. & Boon, A. J. Reliability of a
13 novel ultrasound system for gray-scale analysis of muscle: Muscle Ultrasound Reliability. *Muscle Nerve*
14 **56**, 408–412 (2017).
15
16 118. Roy, B. *et al.* Exploring the relationship between electrical impedance myography and
17 quantitative ultrasound parameters in Duchenne muscular dystrophy. *Clin. Neurophysiol.* **130**, 515–520
18 (2019).
19
20 119. Albano, D., Aringhieri, G., Messina, C., De Flaviis, L. & Sconfienza, L. M. High-Frequency and
21 Ultra-High Frequency Ultrasound: Musculoskeletal Imaging up to 70 MHz. *Semin. Musculoskelet. Radiol.*
22 **24**, 125–134 (2020).
23
24 120. van Alfen, N., Gijsbertse, K. & de Korte, C. L. How useful is muscle ultrasound in the diagnostic
25 workup of neuromuscular diseases? *Curr. Opin. Neurol.* **31**, 568–574 (2018).
26
27 121. Martínez-Payá, J. J. *et al.* Quantitative Muscle Ultrasonography Using Textural Analysis in
28 Amyotrophic Lateral Sclerosis. *Ultrason. Imaging* **39**, 357–368 (2017).
29
30 122. Molinari, F., Caresio, C., Acharya, U. R., Mookiah, M. R. K. & Minetto, M. A. Advances in
31 Quantitative Muscle Ultrasonography Using Texture Analysis of Ultrasound Images. *Ultrasound Med.*
32 *Biol.* **41**, 2520–2532 (2015).
33
34 123. Regensburger, M., Tenner, F., Möbius, C. & Schramm, A. Detection radius of EMG for
35 fasciculations: Empiric study combining ultrasonography and electromyography. *Clin. Neurophysiol.* **129**,
36 487–493 (2018).
37
38 124. Grimm, A. *et al.* Muscle ultrasonography as an additional diagnostic tool for the diagnosis of
39 amyotrophic lateral sclerosis. *Clin. Neurophysiol.* **126**, 820–827 (2015).
40
41 125. Goutman, S. A. *et al.* Speckle tracking as a method to measure hemidiaphragm excursion.
42 *Muscle Nerve* **55**, 125–127 (2017).
43
44 126. Pelosi, L. & Heiss-Dunlop, W. Muscle ultrasound detects subclinical early reinnervation. *Clin.*
45 *Neurophysiol.* **131**, 594–595 (2020).
46
47 127. Alfen, N. V., Nienhuis, M., Zwarts, M. J. & Pillen, S. Detection of fibrillations using muscle
48 ultrasound: Diagnostic accuracy and identification of pitfalls. *Muscle Nerve* **43**, 178–182 (2011).
49
50 128. Pillen, S. *et al.* Muscles alive: Ultrasound detects fibrillations. *Clin. Neurophysiol.* **120**, 932–936
51 (2009).
52
53
54
55
56
57
58
59
60

- 1
2
3 129. van Baalen, A. & Stephani, U. Fibration, fibrillation, and fasciculation: say what you see. *Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol.* **118**, 1418–1420 (2007).
4
5
6 130. Bokuda, K. *et al.* Relationship between EMG-detected and ultrasound-detected fasciculations in
7 amyotrophic lateral sclerosis: A prospective cohort study. *Clin. Neurophysiol.* **131**, 259–264 (2020).
8
9 131. Regensburger, M. Which kinds of fasciculations are missed by ultrasonography in ALS. *Clin.*
10 *Neurophysiol.* **131**, 237–238 (2020).
11
12 132. Regensburger, M., Tenner, F., Möbius, C. & Schramm, A. P 157 Detection radius of EMG for
13 fasciculations: combined ultrasonographic-electromyographic analysis. *Clin. Neurophysiol.* **128**, e404
14 (2017).
15
16 133. Gentile, L. *et al.* Ultrasound guidance increases diagnostic yield of needle EMG in plegic muscle.
17 *Clin. Neurophysiol.* **131**, 446–450 (2020).
18
19 134. Padua, L. *et al.* Ultrasound-guided-electromyography in plegic muscle: Usefulness of nerve
20 stimulation. *Muscle Nerve n/a*, 204–207 (2023).
21
22 135. Stålberg, E. Macro EMG, a new recording technique. *J. Neurol. Neurosurg. Psychiatry* **43**, 475–
23 482 (1980).
24
25 136. Frulio, N. & Trillaud, H. Ultrasound elastography in liver. *Diagn. Interv. Imaging* **94**, 515–534
26 (2013).
27
28 137. MacKay, B. J. *et al.* Evidence-Based Approach to Timing of Nerve Surgery. *Ann. Plast. Surg.* **87**,
29 e1–e21 (2021).
30
31 138. Ewertsen, C., Carlsen, J. F., Christiansen, I. R., Jensen, J. A. & Nielsen, M. B. Evaluation of healthy
32 muscle tissue by strain and shear wave elastography – Dependency on depth and ROI position in
33 relation to underlying bone. *Ultrasonics* **71**, 127–133 (2016).
34
35 139. Kim, S. J., Park, H. J. & Lee, S. Y. Usefulness of strain elastography of the musculoskeletal system.
36 *Ultrason. Ultrason.* **35**, 104–109 (2015).
37
38 140. Martin, M. J. B. & Cartwright, M. S. M. A Pilot Study of Strain Elastography in the Diagnosis of
39 Carpal Tunnel Syndrome. *J. Clin. Neurophysiol.* doi:10.1097/WNP.0000000000000334.
40
41 141. Martínez-Payá, J. J., del Baño-Aledo, M. E., Ríos-Díaz, J., Fornés-Ferrer, V. & Vázquez-Costa, J. F.
42 Sonoelastography for the Assessment of Muscle Changes in Amyotrophic Lateral Sclerosis: Results of a
43 Pilot Study. *Ultrasound Med. Biol.* **44**, 2540–2547 (2018).
44
45 142. Nightingale, K., Soo, M. S., Nightingale, R. & Trahey, G. Acoustic radiation force impulse imaging:
46 in vivo demonstration of clinical feasibility. *Ultrasound Med. Biol.* **28**, 227–235 (2002).
47
48 143. Brandenburg, J. E. *et al.* Ultrasound Elastography: The New Frontier in Direct Measurement of
49 Muscle Stiffness. *Arch. Phys. Med. Rehabil.* **95**, 2207–2219 (2014).
50
51 144. Hossain, M. M., Nichols, T., Merricks, E. & Gallippi, C. Viscoelastic response (VisR)-derived
52 relative elasticity and relative viscosity reflect true elasticity and viscosity, in silico. in *2017 IEEE*
53 *International Ultrasonics Symposium (IUS)* 1–4 (2017). doi:10.1109/ULTSYM.2017.8092884.
54
55
56
57
58
59
60

- 1
2
3 145. Eby, S. F. *et al.* Validation of shear wave elastography in skeletal muscle. *J. Biomech.* **46**, 2381–
4 2387 (2013).
5
6 146. Bamber, J. *et al.* EFSUMB guidelines and recommendations on the clinical use of ultrasound
7 elastography. Part 1: Basic principles and technology. *Ultraschall Med. Stuttg. Ger. 1980* **34**, 169–184
8 (2013).
9
10 147. Kronlage, C. *et al.* Muscle Ultrasound Shear Wave Elastography as a Non-Invasive Biomarker in
11 Myotonia. *Diagnostics* **11**, 163 (2021).
12
13 148. Gennisson, J.-L., Deffieux, T., Fink, M. & Tanter, M. Ultrasound elastography: principles and
14 techniques. *Diagn. Interv. Imaging* **94**, 487–495 (2013).
15
16 149. Barnes, S. L. & Simon, N. G. Clinical and research applications of neuromuscular ultrasound in
17 amyotrophic lateral sclerosis. *Degener. Neurol. Neuromuscul. Dis.* **9**, 89–102 (2019).
18
19 150. Ryu, J. & Jeong, W. K. Current status of musculoskeletal application of shear wave elastography.
20 *Ultrasonography* **36**, 185–197 (2017).
21
22 151. Stecco, A., Pirri, C., De Caro, R. & Raghavan, P. Stiffness and echogenicity: Development of a
23 stiffness-echogenicity matrix for clinical problem solving. *Eur. J. Transl. Myol.* **29**, (2019).
24
25 152. Jerban, S., Barrère, V., Andre, M., Chang, E. Y. & Shah, S. B. Quantitative Ultrasound Techniques
26 Used for Peripheral Nerve Assessment. *Diagnostics* **13**, 956 (2023).
27
28 153. Boom, J. & Visser, L. H. Quantitative assessment of nerve echogenicity: Comparison of methods
29 for evaluating nerve echogenicity in ulnar neuropathy at the elbow. *Clin. Neurophysiol.* **123**, 1446–1453
30 (2012).
31
32 154. Tagliafico, A., Tagliafico, G. & Martinoli, C. Nerve Density: A New Parameter to Evaluate
33 Peripheral Nerve Pathology on Ultrasound. Preliminary Study. *Ultrasound Med. Biol.* **36**, 1588–1593
34 (2010).
35
36 155. Watanabe, T. *et al.* Sonographic Evaluation of the Peripheral Nerve in Diabetic Patients The
37 Relationship Between Nerve Conduction Studies, Echo Intensity, and Cross-sectional Area. *J. Ultrasound*
38 *Med.* **29**, 697–708 (2010).
39
40 156. Beekman, R., Visser, L. H. & Verhagen, W. I. Ultrasonography in ulnar neuropathy at the elbow: a
41 critical review. *Muscle Nerve* **43**, 627–635 (2011).
42
43 157. Tagliafico, A., Tagliafico, G. & Martinoli, C. Quantitative assessment of nerve echogenicity: A
44 promising research tool? *Clin. Neurophysiol.* **124**, 209 (2013).
45
46 158. Downs, M. E. *et al.* Non-invasive peripheral nerve stimulation via focused ultrasound in vivo.
47 *Phys. Med. Biol.* **63**, 035011 (2018).
48
49 159. Izzetti, R. *et al.* Ultra-High Frequency Ultrasound, A Promising Diagnostic Technique: Review of
50 the Literature and Single-Center Experience. *Can. Assoc. Radiol. J.* **72**, 418–431 (2021).
51
52 160. Foster, F. S. *et al.* Principles and applications of ultrasound backscatter microscopy. *IEEE Trans.*
53 *Ultrason. Ferroelectr. Freq. Control* **40**, 608–617 (1993).
54
55
56
57
58
59
60

- 1
2
3 161. Artur Bezugly. High frequency ultrasound study of skin tumors in dermatological and aesthetic
4 practice. *Med. Ultrason.* **17**, (2015).
5
- 6 162. Shook, S. ULTRASOUND OF PERIPHERAL NERVE AND MUSCLE. in *2013 Conference for the*
7 *American Society of Neuroimaging* (2013).
8
- 9 163. Cosgrove, D. O. Ultrasound and Contrast Ultrasound. in *Focal Liver Lesions: Detection,*
10 *Characterization, Ablation* (eds. Lencioni, R., Cioni, D. & Bartolozzi, C.) 3–16 (Springer, 2005).
11 doi:10.1007/3-540-26354-3_1.
12
- 13 164. Byra, M. *et al.* Quantitative Ultrasound and B-Mode Image Texture Features Correlate with
14 Collagen and Myelin Content in Human Ulnar Nerve Fascicles. *Ultrasound Med. Biol.* **45**, 1830–1840
15 (2019).
16
- 17 165. Jakubovic, R. *et al.* High-Frequency Micro-Ultrasound Imaging and Optical Topographic Imaging
18 for Spinal Surgery: Initial Experiences. *Ultrasound Med. Biol.* **44**, 2379–2387 (2018).
19
- 20 166. Viviano, S. L., Chandler, L. K. & Keith, J. D. Ultrahigh Frequency Ultrasound Imaging of the Hand:
21 A New Diagnostic Tool for Hand Surgery. *HAND* **13**, 720–725 (2018).
22
- 23 167. Paluch, L. *et al.* Shear-wave elastography: a new potential method to diagnose ulnar neuropathy
24 at the elbow. *Eur. Radiol.* **28**, 4932–4939 (2018).
25
- 26 168. He, Y., Xiang, X., Zhu, B.-H. & Qiu, L. Shear wave elastography evaluation of the median and
27 tibial nerve in diabetic peripheral neuropathy. *Quant. Imaging Med. Surg.* **9**, 27382–27282 (2019).
28
- 29 169. Dikici, A. S. *et al.* Evaluation of the Tibial Nerve with Shear-Wave Elastography: *Musculoskelet.*
30 *IMAGING* **282**, 8 (2017).
31
- 32 170. Ishibashi, F. *et al.* Elasticity of the tibial nerve assessed by sonoelastography was reduced before
33 the development of neuropathy and further deterioration associated with the severity of neuropathy in
34 patients with type 2 diabetes. *J. Diabetes Investig.* **7**, 404–412 (2016).
35
- 36 171. Aslan, M. *et al.* Assessment of Peripheral Nerves With Shear Wave Elastography in Type 1
37 Diabetic Adolescents Without Diabetic Peripheral Neuropathy. *J. Ultrasound Med.* **38**, 1583–1596
38 (2019).
39
- 40 172. Wei, M. & Ye, X. Feasibility of Point Shear Wave Elastography for Evaluating Diabetic Peripheral
41 Neuropathy. *J. Ultrasound Med.* **39**, 1135–1141 (2020).
42
- 43 173. Tang, X. *et al.* Preliminary study on the influencing factors of shear wave elastography for
44 peripheral nerves in healthy population. *Sci. Rep.* **11**, 5582 (2021).
45
- 46 174. Bedewi, M. A. *et al.* Shear wave elastography of the tibial nerve in healthy subjects. *Medicine*
47 *(Baltimore)* **100**, e23999 (2021).
48
- 49 175. Zhu, B. *et al.* Evaluation of the healthy median nerve elasticity Feasibility and reliability of shear
50 wave elastography. *Medicine (Baltimore)* **97**, (2018).
51
- 52 176. Wee, T. C. & Simon, N. G. Ultrasound elastography for the evaluation of peripheral nerves: A
53 systematic review. *Muscle Nerve* **60**, 501–512 (2019).
54
55
56
57
58
59
60

177. Schrier, V. J. M. M. *et al.* Shear wave elastography of the median nerve: A mechanical study. *Muscle Nerve* **61**, 826–833 (2020).
178. Rugel, C., Franz, C. & Lee, S. Influence of limb position on assessment of nerve mechanical properties by using shear wave ultrasound elastography. *MUSCLE NERVE* **61**, 616–622 (2020).
179. Moon, J. H., Hwang, J.-Y., Park, J. S., Koh, S. H. & Park, S.-Y. Impact of region of interest (ROI) size on the diagnostic performance of shear wave elastography in differentiating solid breast lesions. *Acta Radiol.* **59**, 657–663 (2018).
180. Mulabecirovic, A., Vesterhus, M., Gilja, O. H. & Havre, R. F. In Vitro Comparison of Five Different Elastography Systems for Clinical Applications, Using Strain and Shear Wave Technology. *Ultrasound Med. Biol.* **42**, 2572–2588 (2016).
181. Dillman, J. R. *et al.* Superficial ultrasound shear wave speed measurements in soft and hard elasticity phantoms: repeatability and reproducibility using two ultrasound systems. *Pediatr. Radiol.* **45**, 376–385 (2015).
182. Shin, H. J., Kim, M.-J., Kim, H. Y., Roh, Y. H. & Lee, M.-J. Comparison of shear wave velocities on ultrasound elastography between different machines, transducers, and acquisition depths: a phantom study. *Eur. Radiol.* **26**, 3361–3367 (2016).
183. Greening, J. & Dilley, A. Posture-induced changes in peripheral nerve stiffness measured by ultrasound shear-wave elastography: Nerve Shear-wave Elastography. *MUSCLE NERVE* **55**, 213–222 (2017).
184. Zakrzewski, J., Zakrzewska, K., Pluta, K., Nowak, O. & Miłoszewska-Paluch, A. Ultrasound elastography in the evaluation of peripheral neuropathies: a systematic review of the literature. *Pol. J. Radiol.* **84**, 581–591 (2019).
185. Nam, K., Peterson, S. M., Wessner, C. E., Machado, P. & Forsberg, F. Diagnosis of Carpal Tunnel Syndrome using Shear Wave Elastography and High-frequency Ultrasound Imaging. *Acad. Radiol.* **28**, e278–e287 (2021).
186. Moran, L. *et al.* Carpal Tunnel Syndrome: Diagnostic Usefulness of Ultrasound Measurement of the Median Nerve Area and Quantitative Elastographic Measurement of the Median Nerve Stiffness. *J. Ultrasound Med.* **39**, 331–339 (2020).
187. Miyamoto, H. *et al.* Carpal Tunnel Syndrome: Diagnosis by Means of Median Nerve Elasticity—Improved Diagnostic Accuracy of US with Sonoelastography. *Radiology* **270**, 481–486 (2014).
188. Mohammadi, A., Ghasemi-Rad, M., Mladkova-Suchy, N. & Ansari, S. Correlation between the severity of carpal tunnel syndrome and color Doppler sonography findings. *AJR Am. J. Roentgenol.* **198**, W181-184 (2012).
189. Wee, T. C. & Simon, N. G. Shearwave Elastography in the Differentiation of Carpal Tunnel Syndrome Severity. *PM R* **12**, 1134–1139 (2020).
190. Ibrahim, H. R. Diagnostic value of median nerve shear wave ultrasound elastography in diagnosis and differentiation of carpal tunnel syndrome severity. *Egypt. J. Radiol. Nucl. Med.* **52**, 187 (2021).

- 1
2
3 191. Chen, J. *et al.* Value of superb microvascular imaging ultrasonography in the diagnosis of carpal
4 tunnel syndrome: Compared with color Doppler and power Doppler. *Medicine (Baltimore)* **96**, e6862
5 (2017).
6
7 192. Paluch, Ł., Pietruski, P., Walecki, J. & Noszczyk, B. H. Wrist to forearm ratio as a median nerve
8 shear wave elastography test in carpal tunnel syndrome diagnosis. *J. Plast. Reconstr. Aesthet. Surg.* **71**,
9 1146–1152 (2018).
10
11 193. Wang, T., Qi, H., Chen, C. & Teng, J. Study on the Crush Injury Model of the Sciatic Nerve in
12 Rabbits by Conventional Ultrasound and Elastography. *Curr. Med. Imaging Former. Curr. Med. Imaging*
13 *Rev.* **19**, 764–769 (2023).
14
15 194. Zhu, Y. *et al.* Evaluation of the Crushed Sciatic Nerve and Denervated Muscle with Multimodality
16 Ultrasound Techniques: An Animal Study. *Ultrasound Med. Biol.* **46**, 377–392 (2020).
17
18 195. Kesikburun, S., Adigüzel, E., Kesikburun, B. & Yaşar, E. Sonoelastographic Assessment of the
19 Median Nerve in the Longitudinal Plane for Carpal Tunnel Syndrome. *PM&R* **8**, 183–185 (2016).
20
21 196. Wang, Y., Tang, P., Zhang, L., Guo, Y. & Wan, W. Quantitative evaluation of the peripheral nerve
22 blood perfusion with high frequency contrast-enhanced ultrasound. *Acad. Radiol.* **17**, 1492–1497 (2010).
23
24 197. Kele, H. Ultrasonography of the peripheral nervous system. *Perspect. Med.* **1**, 417–421 (2012).
25
26 198. Suk, J. I., Walker, F. O. & Cartwright, M. S. Ultrasound of Peripheral Nerves. *Curr. Neurol.*
27 *Neurosci. Rep.* **13**, 328 (2013).
28
29 199. Tegtmeier, K., Abboud, S. F., Omar, I. M., Grant, T. & Deshmukh, S. Musculoskeletal Ultrasound
30 of Rheumatologic Conditions. *Adv. Clin. Radiol.* **3**, 169–182 (2021).
31
32 200. Wong, S. M. *et al.* Carpal Tunnel Syndrome: Diagnostic Usefulness of Sonography. *Radiology*
33 **232**, 93–99 (2004).
34
35 201. Mallouhi, A. *et al.* Predictors of carpal tunnel syndrome: accuracy of gray-scale and color
36 Doppler sonography. *AJR Am. J. Roentgenol.* **186**, 1240–1245 (2006).
37
38 202. Réaux-Le-Goazigo, A. *et al.* Ultrasound localization microscopy and functional ultrasound
39 imaging reveal atypical features of the trigeminal ganglion vasculature. *Commun. Biol.* **5**, 330 (2022).
40
41 203. In Vitro Comparison of Five Different Elastography Systems for Clinical Applications, Using Strain
42 and Shear Wave Technology - PubMed. <https://pubmed.ncbi.nlm.nih.gov/27570209/>.
43
44 204. Beard, P. Biomedical photoacoustic imaging. *Interface Focus* **1**, 602–631 (2011).
45
46 205. Ntziachristos, V. & Razansky, D. Molecular Imaging by Means of Multispectral Optoacoustic
47 Tomography (MSOT). *Chem. Rev.* **110**, 2783–2794 (2010).
48
49 206. Bodea, S.-V. & Westmeyer, G. G. Photoacoustic Neuroimaging - Perspectives on a Maturing
50 Imaging Technique and its Applications in Neuroscience. *Front. Neurosci.* **15**, (2021).
51
52 207. Taruttis, A. & Ntziachristos, V. Advances in real-time multispectral optoacoustic imaging and its
53 applications. *Nat. Photonics* **9**, 219–227 (2015).
54
55
56
57
58
59
60

- 1
2
3 208. Omar, M., Soliman, D., Gateau, J. & Ntziachristos, V. Ultrawideband reflection-mode
4 optoacoustic mesoscopy. *Opt. Lett.* **39**, 3911–3914 (2014).
5
6 209. Chaigne, T., Arnal, B., Vilov, S., Bossy, E. & Katz, O. Super-resolution photoacoustic imaging via
7 flow-induced absorption fluctuations. *Optica* **4**, 1397–1404 (2017).
8
9 210. Schwarz, M. *et al.* Optoacoustic Dermoscopy of the Human Skin: Tuning Excitation Energy for
10 Optimal Detection Bandwidth With Fast and Deep Imaging in vivo. *IEEE Trans. Med. Imaging* **36**, 1287–
11 1296 (2017).
12
13 211. Soliman, D., Tserevelakis, G. J., Omar, M. & Ntziachristos, V. Combining microscopy with
14 mesoscopy using optical and optoacoustic label-free modes. *Sci. Rep.* **5**, 12902 (2015).
15
16 212. Jeon, S., Kim, J., Lee, D., Baik, J. W. & Kim, C. Review on practical photoacoustic microscopy.
17 *Photoacoustics* **15**, 100141 (2019).
18
19 213. Fan, Q. *et al.* Transferring Biomarker into Molecular Probe: Melanin Nanoparticle as a Naturally
20 Active Platform for Multimodality Imaging. *J. Am. Chem. Soc.* **136**, 15185–15194 (2014).
21
22 214. Guggenheim, J. A. *et al.* Photoacoustic imaging of human lymph nodes with endogenous lipid
23 and hemoglobin contrast. *J. Biomed. Opt.* **20**, 1 (2015).
24
25 215. Graham, M. T., von Guionneau, N., Tuffaha, S. & Lediju Bell, M. A. Design and optimization of
26 simulated light delivery systems for photoacoustic assessment of peripheral nerve injury. in *Photons Plus*
27 *Ultrasound: Imaging and Sensing 2022* (eds. Oraevsky, A. A. & Wang, L. V.) 169 (SPIE, 2022).
28 doi:10.1117/12.2610511.
29
30 216. Ishihara, M. *et al.* Performance validation of improved photoacoustic / ultrasound superposed
31 imaging system for evaluation of diabetic neuropathy. in *Photons Plus Ultrasound: Imaging and Sensing*
32 *2019* vol. 10878 433–440 (SPIE, 2019).
33
34 217. Mari, J. M., West, S., Beard, P. C. & Desjardins, A. E. Multispectral photoacoustic imaging of
35 nerves with a clinical ultrasound system. in *Photons Plus Ultrasound: Imaging and Sensing 2014* vol.
36 8943 148–154 (SPIE, 2014).
37
38 218. Mari, J. M., Xia, W., West, S. J. & Desjardins, A. E. Interventional multispectral photoacoustic
39 imaging with a clinical ultrasound probe for discriminating nerves and tendons: an ex vivo pilot study. *J.*
40 *Biomed. Opt.* **20**, 110503 (2015).
41
42 219. Jüstel, D. *et al.* Spotlight on nerves: Portable multispectral optoacoustic imaging of peripheral
43 nerve vascularization and morphology.
44
45 220. Li, R., Phillips, E., Wang, P., Goergen, C. J. & Cheng, J.-X. Label-free in vivo imaging of peripheral
46 nerve by multispectral photoacoustic tomography. *J. Biophotonics* **9**, 124–128 (2016).
47
48 221. Matthews, T. P., Zhang, C., Yao, D.-K., Maslov, K. I. & Wang, L. V. Label-free photoacoustic
49 microscopy of peripheral nerves. *J. Biomed. Opt.* **19**, 1 (2014).
50
51 222. Bell, A. G. Upon the production of sound by radiant energy. *Am. J. Sci.* **s3-21**, 463–490 (1881).
52
53 223. Steinberg, I. *et al.* Photoacoustic clinical imaging. *Photoacoustics* **14**, 77–98 (2019).
54
55
56
57
58
59
60

- 1
2
3 224. Vu, T., Razansky, D. & Yao, J. Listening to tissues with new light: recent technological advances in
4 photoacoustic imaging. *J. Opt.* **21**, 103001 (2019).
5
- 6 225. Du, J., Yang, S., Qiao, Y., Lu, H. & Dong, H. Recent progress in near-infrared photoacoustic
7 imaging. *Biosens. Bioelectron.* **191**, 113478 (2021).
8
- 9 226. Dong, B., Yao, J. & Deán-Ben, X. L. Editorial: Advances in Photoacoustic Neuroimaging. *Front.*
10 *Neurosci.* (2022) doi:10.3389/fnins.2022.859515.
11
- 12 227. A review of clinical photoacoustic imaging: Current and future trends. *Photoacoustics* **16**,
13 100144 (2019).
14
- 15 228. Ovsepian, S. V., Olefir, I., Westmeyer, G., Razansky, D. & Ntziachristos, V. Pushing the
16 Boundaries of Neuroimaging with Optoacoustics. *Neuron* **96**, 966–988 (2017).
17
- 18 229. Das, D., Sharma, A., Rajendran, P. & Pramanik, M. Another decade of photoacoustic imaging.
19 *Phys. Med. Biol.* **66**, 05TR01 (2021).
20
- 21 230. Lengenfelder, B. *et al.* Remote photoacoustic sensing using speckle-analysis. *Sci. Rep.* **9**, 1057
22 (2019).
23
- 24 231. Wang, L. V. & Hu, S. Photoacoustic Tomography: In Vivo Imaging from Organelles to Organs.
25 *Science* **335**, 1458–1462 (2012).
26
- 27 232. Wu, W., Wang, P., Cheng, J.-X. & Xu, X.-M. Assessment of White Matter Loss Using Bond-
28 Selective Photoacoustic Imaging in a Rat Model of Contusive Spinal Cord Injury. *J. Neurotrauma* **31**,
29 1998–2002 (2014).
30
- 31 233. Luzhansky, I. D., Sudlow, L. C., Brogan, D. M., Wood, M. D. & Berezin, M. Y. Imaging in the repair
32 of peripheral nerve injury. *Nanomed.* **14**, 2659–2677 (2019).
33
- 34 234. Chen, K.-T., Wei, K.-C. & Liu, H.-L. Theranostic Strategy of Focused Ultrasound Induced Blood-
35 Brain Barrier Opening for CNS Disease Treatment. *Front. Pharmacol.* **10**, 86 (2019).
36
- 37 235. Zhu, Y. *et al.* Light Emitting Diodes based Photoacoustic Imaging and Potential Clinical
38 Applications. *Sci. Rep.* **8**, 9885 (2018).
39
- 40 236. Lin, L. & Wang, L. V. Photoacoustic Imaging. in (eds. Wei, X. & Gu, B.) 147–175 (Springer
41 Singapore, 2021).
42
- 43 237. Plumb, A. A., Huynh, N. T., Guggenheim, J., Zhang, E. & Beard, P. Rapid volumetric photoacoustic
44 tomographic imaging with a Fabry-Perot ultrasound sensor depicts peripheral arteries and microvascular
45 vasomotor responses to thermal stimuli. *Eur. Radiol.* **28**, 1037–1045 (2018).
46
- 47 238. Wissmeyer, G., Pleitez, M. A., Rosenthal, A. & Ntziachristos, V. Looking at sound: optoacoustics
48 with all-optical ultrasound detection. *Light Sci. Appl.* **7**, 53 (2018).
49
- 50 239. Rosenthal, A., Ntziachristos, V. & Razansky, D. Acoustic Inversion in Optoacoustic Tomography: A
51 Review. *Curr. Med. Imaging Rev.* **9**, 318–336 (2013).
52
53
54
55
56
57
58
59
60

- 1
2
3 240. Gottschalk, S. *et al.* Rapid volumetric optoacoustic imaging of neural dynamics across the mouse
4 brain. *Nat. Biomed. Eng.* **3**, 392–401 (2019).
5
- 6 241. Shen, C. *et al.* An introduction to deep learning in medical physics: advantages, potential, and
7 challenges. *Phys. Med. Biol.* **65**, 05TR01 (2020).
8
- 9 242. Pradhan, P., Guo, S., Ryabchykov, O., Popp, J. & Bocklitz, T. W. Deep learning a boon for
10 biophotonics? *J. Biophotonics* **13**, e201960186 (2020).
11
- 12 243. Hysi, E., Moore, M. J., Strohm, E. M. & Kolios, M. C. A tutorial in photoacoustic microscopy and
13 tomography signal processing methods. *J. Appl. Phys.* **129**, 141102 (2021).
14
- 15 244. Luís Dean-Ben, X. & Razansky, D. Localization optoacoustic tomography. *Light Sci. Appl.* **7**,
16 18004–18004 (2018).
17
- 18 245. Yu, Z. *et al.* Wavefront shaping: A versatile tool to conquer multiple scattering in
19 multidisciplinary fields. *The Innovation* **3**, 100292 (2022).
20
- 21 246. Lai, P., Wang, L., Tay, J. W. & Wang, L. V. Photoacoustically guided wavefront shaping for
22 enhanced optical focusing in scattering media. *Nat. Photonics* **9**, 126–132 (2015).
23
- 24 247. Dertinger, T., Colyer, R., Iyer, G., Weiss, S. & Enderlein, J. Fast, background-free, 3D super-
25 resolution optical fluctuation imaging (SOFI). *Proc. Natl. Acad. Sci.* **106**, 22287–22292 (2009).
26
- 27 248. Conkey, D. B. *et al.* Super-resolution photoacoustic imaging through a scattering wall. *Nat.*
28 *Commun.* **6**, 7902 (2015).
29
- 30 249. Behera, D., Jacobs, K. E., Behera, S., Rosenberg, J. & Biswal, S. 18 F-FDG PET/MRI Can Be Used to
31 Identify Injured Peripheral Nerves in a Model of Neuropathic Pain. *J. Nucl. Med.* **52**, 1308–1312 (2011).
32
- 33 250. Rangavajla, G., Mokarram, N., Masoodzadehgan, N., Pai, S. B. & Bellamkonda, R. V. Noninvasive
34 Imaging of Peripheral Nerves. *Cells Tissues Organs* **200**, 69–77 (2015).
35
- 36 251. Nam, J. W., Lee, M. J. & Kim, H. J. Diagnostic Efficacy of 18F-FDG PET/MRI in Peripheral Nerve
37 Injury Models. *Neurochem. Res.* **44**, 2092–2102 (2019).
38
- 39 252. Stoll, G., Israel, I., Deiss, A. & Samnik, S. Macrophage imaging in experimental nerve injury by
40 68GA-dotatate: A combined autoradiography/pet study - Record details - Embase. in *Journal of the*
41 *Peripheral Nervous System* vol. 21 214 (2016).
42
- 43 253. Ewertsen, C., Săftoiu, A., Gruionu, L. G., Karstrup, S. & Nielsen, M. B. Real-Time Image Fusion
44 Involving Diagnostic Ultrasound. *Am. J. Roentgenol.* **200**, W249–W255 (2013).
45
- 46 254. Wein, W. *et al.* Global Registration of Ultrasound to MRI Using the LC2 Metric for Enabling
47 Neurosurgical Guidance. in *Medical Image Computing and Computer-Assisted Intervention – MICCAI*
48 *2013* (eds. Mori, K., Sakuma, I., Sato, Y., Barillot, C. & Navab, N.) 34–41 (Springer, 2013).
49 doi:10.1007/978-3-642-40811-3_5.
50
- 51 255. Chopra, S. S. *et al.* Development and validation of a three dimensional ultrasound based
52 navigation system for tumor resection. *Eur. J. Surg. Oncol. EJSO* **34**, 456–461 (2008).
53
54
55
56
57
58
59
60

- 1
2
3 256. Heinrich, M. P. Intra-operative Ultrasound to MRI Fusion with a Public Multimodal Discrete
4 Registration Tool. in *Simulation, Image Processing, and Ultrasound Systems for Assisted Diagnosis and*
5 *Navigation* (eds. Stoyanov, D. et al.) 159–164 (Springer International Publishing, 2018). doi:10.1007/978-
6 3-030-01045-4_19.
7
8 257. Attia, A. B. E. *et al.* Multispectral optoacoustic and MRI coregistration for molecular imaging of
9 orthotopic model of human glioblastoma. *J. Biophotonics* **9**, 701–708 (2016).
10
11 258. Lee, C., Choi, W., Kim, J. & Kim, C. Three-dimensional clinical handheld
12 photoacoustic/ultrasound scanner. *Photoacoustics* **18**, 100173 (2020).
13
14 259. Bilgen, M. *et al.* Microneurography of human median nerve. *J. Magn. Reson. Imaging JMRI* **21**,
15 826–830 (2005).
16
17 260. Yoon, D., Biswal, S., Rutt, B., Lutz, A. & Hargreaves, B. Feasibility of 7T MRI for Imaging Fascicular
18 Structures of Peripheral Nerves. *Muscle Nerve* **57**, 494–498 (2018).
19
20 261. Felisaz, P. F. *et al.* In Vivo MR Microneurography of the Tibial and Common Peroneal Nerves.
21 *Radiol. Res. Pract.* **2014**, 1–6 (2014).
22
23 262. Riegler, G. *et al.* High-Resolution Axonal Bundle (Fascicle) Assessment and Triple-Echo Steady-
24 State T2 Mapping of the Median Nerve at 7 T: Preliminary Experience. *Invest. Radiol.* **51**, 529–535
25 (2016).
26
27 263. Zochowski, K. C. *et al.* Improvement of peripheral nerve visualization using a deep learning-
28 based MR reconstruction algorithm. *Magn. Reson. Imaging* **85**, 186–192 (2022).
29
30 264. Felisaz, P. F. *et al.* Nerve Fascicles and Epineurium Volume Segmentation of Peripheral Nerve
31 Using Magnetic Resonance Micro-neurography. *Acad. Radiol.* **23**, 1000–1007 (2016).
32
33 265. Evans, M. C. *et al.* Magnetic Resonance Imaging as a Biomarker in Diabetic and HIV-Associated
34 Peripheral Neuropathy: A Systematic Review-Based Narrative. *Front. Neurosci.* **15**, 727311 (2021).
35
36 266. Sodickson, D. K., Griswold, M. A., Jakob, P. M., Edelman, R. R. & Manning, W. J. Signal-to-noise
37 ratio and signal-to-noise efficiency in SMASH imaging. *Magn. Reson. Med.* **41**, 1009–1022 (1999).
38
39 267. Lustig, M., Donoho, D. & Pauly, J. M. Sparse MRI: The application of compressed sensing for
40 rapid MR imaging. *Magn. Reson. Med.* **58**, 1182–1195 (2007).
41
42 268. Felisaz, P. *et al.* MR microneurography and quantitative T2 and DP measurements of the distal
43 tibial nerve in CIDP. *J. Neurol. Sci.* **400**, 15–20 (2019).
44
45 269. Shung, K. K. High Frequency Ultrasonic Imaging. *J. Med. Ultrasound* **17**, 25–30 (2009).
46
47 270. Pavlin, C. J., Harasiewicz, K., Sherar, M. D. & Foster, F. S. Clinical Use of Ultrasound
48 Biomicroscopy. *Ophthalmology* **98**, 287–295 (1991).
49
50 271. Foster, F. S., Pavlin, C. J., Harasiewicz, K. A., Christopher, D. A. & Turnbull, D. H. Advances in
51 ultrasound biomicroscopy. *Ultrasound Med. Biol.* **26**, 1–27 (2000).
52
53
54
55
56
57
58
59
60

- 1
2
3 272. Henry, F. P. *et al.* In vivo optical microscopy of peripheral nerve myelination with polarization
4 sensitive-optical coherence tomography. *J. Biomed. Opt.* **20**, 046002 (2015).
5
6 273. Nam, A. *et al.* Wide-Field Functional Microscopy of Peripheral Nerve Injury and Regeneration.
7 *Sci. Rep.* **8**, (2018).
8
9 274. Bélanger, E. *et al.* Quantitative myelin imaging with coherent anti-Stokes Raman scattering
10 microscopy: alleviating the excitation polarization dependence with circularly polarized laser beams.
11 *Opt. Express* **17**, 18419 (2009).
12
13 275. Jung, Y. *et al.* Comprehensive Evaluation of Peripheral Nerve Regeneration in the Acute Healing
14 Phase Using Tissue Clearing and Optical Microscopy in a Rodent Model. *PLoS ONE* **9**, e94054 (2014).
15
16 276. Fujimoto, J. G., Pitris, C., Boppart, S. A. & Brezinski, M. E. Optical Coherence Tomography: An
17 Emerging Technology for Biomedical Imaging and Optical Biopsy. *Neoplasia N. Y. N* **2**, 9–25 (2000).
18
19 277. Cotero, V. E. *et al.* Improved Intraoperative Visualization of Nerves through a Myelin-Binding
20 Fluorophore and Dual-Mode Laparoscopic Imaging. *PLOS ONE* **10**, e0130276 (2015).
21
22 278. Walsh, E. M. *et al.* Fluorescence Imaging of Nerves During Surgery. *Ann. Surg.* **270**, 69–76 (2019).
23
24 279. Gibbs-Strauss, S. L. *et al.* Nerve-Highlighting Fluorescent Contrast Agents for Image-Guided
25 Surgery. *Mol. Imaging* **10**, 7290.2010.00026 (2011).
26
27 280. Yan, Y. Evaluation of peripheral nerve regeneration via in vivo serial transcutaneous imaging
28 using transgenic Thy1-YFP mice. *Exp. Neurol.* **8** (2011).
29
30 281. Bremer, J., Skinner, J. & Granato, M. A small molecule screen identifies in vivo modulators of
31 peripheral nerve regeneration in zebrafish. *PLoS ONE* **12**, e0178854 (2017).
32
33 282. Placheta, E. *et al.* Macroscopic In Vivo Imaging of Facial Nerve Regeneration in *Thy1 - GFP* Rats.
34 *JAMA Facial Plast. Surg.* **17**, 8–15 (2015).
35
36 283. MicroCT optimisation for imaging fascicular anatomy in peripheral nerves. *J. Neurosci. Methods*
37 **338**, 108652 (2020).
38
39 284. Heimel, P. *et al.* Iodine-Enhanced Micro-CT Imaging of Soft Tissue on the Example of Peripheral
40 Nerve Regeneration. *Contrast Media Mol. Imaging* **2019**, 7483745–15 (2019).
41
42 285. Morisaki, S. *et al.* Application of Raman spectroscopy for visualizing biochemical changes during
43 peripheral nerve injury *in vitro* and *in vivo*. *J. Biomed. Opt.* **18**, 116011 (2013).
44
45 286. Kumamoto, Y., Harada, Y., Tanaka, H. & Takamatsu, T. Rapid and accurate peripheral nerve
46 imaging by multipoint Raman spectroscopy. *Sci. Rep.* **7**, 845 (2017).
47
48 287. Boon, A. J. Neuromuscular Ultrasound in the EMG Laboratory. in *Clinical Neurophysiology* (eds.
49 Rubin, D. I. & Rubin, D. I.) 0 (Oxford University Press, 2021).
50 doi:10.1093/med/9780190067854.003.0037.
51
52 288. Preston, D. C. & Shapiro, B. E. *Electromyography and neuromuscular disorders e-book: clinical-*
53 *electrophysiologic-ultrasound correlations.* (Elsevier Health Sciences, 2020).
54
55
56
57
58
59
60

- 1
2
3 289. Strommen, J. A., Skinner, S. & Crum, B. A. Neurophysiology during peripheral nerve surgery. in
4 *Handbook of Clinical Neurology* vol. 186 295–318 (Elsevier, 2022).
5
6 290. Haldeman, C. L., Baggott, C. D. & Hanna, A. S. Intraoperative ultrasound-assisted peripheral
7 nerve surgery. *Neurosurg. Focus* **39**, E4 (2015).
8
9 291. Koenig, R. W. *et al.* Intraoperative high-resolution ultrasound: a new technique in the
10 management of peripheral nerve disorders: Clinical article. *J. Neurosurg.* **114**, 514–521 (2011).
11
12 292. Burks, S. S., Cajigas, I., Jose, J. & Levi, A. D. Intraoperative Imaging in Traumatic Peripheral Nerve
13 Lesions: Correlating Histologic Cross-Sections with High-Resolution Ultrasound. *Oper. Neurosurg.* **13**,
14 196–203 (2017).
15
16 293. Chiou, H.-J., Chou, Y.-H., Chiou, S.-Y., Liu, J.-B. & Chang, C.-Y. Peripheral nerve lesions: role of
17 high-resolution US. *Radiographics* **23**, e15–e15 (2003).
18
19 294. Gofeld, M., Bristow, S. J., Chiu, S. & Kliot, M. Preoperative ultrasound-guided mapping of
20 peripheral nerves: Laboratory investigation. *J. Neurosurg.* **119**, 709–713 (2013).
21
22 295. Boczar, D. *et al.* Intraoperative evaluation of cervical nerve root avulsion using ultra-high-
23 frequency ultrasound system. *Case Rep. Plast. Surg. Hand Surg.* **6**, 43–46 (2019).
24
25 296. Forte, A. J., Boczar, D., Oliver, J. D., Sisti, A. & Clendenen, S. R. Ultra-high-frequency Ultrasound
26 to Assess Nerve Fascicles in Median Nerve Traumatic Neuroma. *Cureus* **11**, e4871.
27
28 297. Hayashi, A. *et al.* Ultra High-frequency Ultrasonographic Imaging with 70 MHz Scanner for
29 Visualization of the Lymphatic Vessels. *Plast. Reconstr. Surg. – Glob. Open* **7**, e2086 (2019).
30
31 298. Yeoh, S. *et al.* Incorporating Blood Flow in Nerve Injury and Regeneration Assessment. *Front.*
32 *Surg.* **9**, 862478 (2022).
33
34 299. Ogata, K. & Naito, M. Blood flow of peripheral nerve effects of dissection stretching and
35 compression. *J. Hand Surg. Br. Eur. Vol.* **11**, 10–14 (1986).
36
37 300. Artul, S., Nseir, W., Armaly, Z. & Soudack, M. Superb Microvascular Imaging: Added Value and
38 Novel Applications. *J. Clin. Imaging Sci.* **7**, 45 (2017).
39
40 301. Járay, Á., Farkas, P. I., Semjén, D., Battyáni, I. & Botz, B. Additional value of microvascular flow
41 imaging in the assessment of cystic and solid renal lesions. *Physiol. Int.* **110**, 52–63 (2023).
42
43 302. Höke, A., Sun, H. S., Gordon, T. & Zochodne, D. W. Do denervated peripheral nerve trunks
44 become ischemic? The impact of chronic denervation on vasa nervorum. *Exp. Neurol.* **172**, 398–406
45 (2001).
46
47 303. Lee, C., Lee, D., Zhou, Q., Kim, J. & Kim, C. Real-time Near-infrared Virtual Intraoperative Surgical
48 Photoacoustic Microscopy. *Photoacoustics* **3**, 100–106 (2015).
49
50 304. Abbasi, S. *et al.* All-optical Reflection-mode Microscopic Histology of Unstained Human Tissues.
51 *Sci. Rep.* **9**, 13392 (2019).
52
53
54
55
56
57
58
59
60

1
2
3 305. Ecclestone, B. R. *et al.* Improving maximal safe brain tumor resection with photoacoustic remote
4 sensing microscopy. *Sci. Rep.* **10**, 17211 (2020).
5

6 306. Ravagli, E. *et al.* Fascicle localisation within peripheral nerves through evoked activity
7 recordings: A comparison between electrical impedance tomography and multi-electrode arrays. *J.*
8 *Neurosci. Methods* 109140 (2021) doi:10.1016/j.jneumeth.2021.109140.
9

10 307. Ravagli, E. *et al.* Imaging fascicular organization of rat sciatic nerves with fast neural electrical
11 impedance tomography. *Nat. Commun.* **11**, 6241 (2020).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60